Noninvasive multi-parameter patient monitor

Information

  • Patent Grant
  • 9131882
  • Patent Number
    9,131,882
  • Date Filed
    Friday, October 11, 2013
    10 years ago
  • Date Issued
    Tuesday, September 15, 2015
    8 years ago
Abstract
Embodiments of the present disclosure include a handheld multi-parameter patient monitor capable of determining multiple physiological parameters from the output of a light sensitive detector capable of detecting light attenuated by body tissue. For example, in an embodiment, the monitor is capable of advantageously and accurately displaying one or more of pulse rate, plethysmograph data, perfusion quality, signal confidence, and values of blood constituents in body tissue, including for example, arterial carbon monoxide saturation (“HbCO”), methemoglobin saturation (“HbMet”), total hemoglobin (“Hbt”), arterial oxygen saturation (“SpO2”), fractional arterial oxygen saturation (“SpaO2”), or the like. The monitor can determine which a plurality of light emitting sources and which of a plurality of parameters to measure based on the signal quality and resources available.
Description
INCORPORATION BY REFERENCE OF RELATED UTILITY APPLICATIONS

The present application is related to the following copending U.S. utility applications:


















App. Sr. No.
Filing Date
Title




















1
11/367,013
Mar. 1, 2006
Multiple Wavelength






Sensor Emitters



2
11/366,995
Mar. 1, 2006
Multiple Wavelength






Sensor Equalization



3
11/366,209
Mar. 1, 2006
Multiple Wavelength






Sensor Substrate



4
11/366,210
Mar. 1, 2006
Multiple Wavelength






Sensor Interconnect



5
11/366,833
Mar. 1, 2006
Multiple Wavelength






Sensor Attachment



6
11/366,997
Mar. 1, 2006
Multiple Wavelength






Sensor Drivers



7
11/367,034
Mar. 1, 2006
Physiological






Parameter






Confidence Measure



8
11/367,036
Mar. 1, 2006
Configurable






Physiological






Measurement System



9
11/367,033
Mar. 1, 2006
Noninvasive Multi-






Parameter Patient






Monitor



10
11/367,014
Mar. 1, 2006
Noninvasive Multi-






Parameter Patient






Monitor



11
11/366,208
Mar. 1, 2006
Noninvasive Multi-






Parameter Patient






Monitor



12
13/412,428
Mar. 5, 2012
Noninvasive Multi-






Parameter Patient






Monitor



13
12/949,271
Nov. 18, 2010
Physiological






Measurement System






with Automatic






Wavelength






Adjustment









The present application incorporates the foregoing disclosures herein by reference.


FIELD OF THE DISCLOSURE

The present disclosure relates to the field of noninvasive patient monitors. More specifically, the disclosure relates to monitors displaying measurements derived using signals from optical sensors.


BACKGROUND

Spectroscopy is a common technique for measuring the concentration of organic and some inorganic constituents of a solution. The theoretical basis of this technique is the Beer-Lambert law, which states that the concentration ci of an absorbent in solution can be determined by the intensity of light transmitted through the solution, knowing the pathlength dλ, the intensity of the incident light I0,λ, and the extinction coefficient εi,λ at a particular wavelength λ. In generalized form, the Beer-Lambert law is expressed as:










I
λ

=


I

0
,
λ







-

d
λ


·

μ

0
,
λ









(
1
)







μ

0
,
λ


=




i
=
1

n








ɛ

i
,
λ


·

c
i







(
2
)







where μ0,λ is the bulk absorption coefficient and represents the probability of absorption per unit length. The minimum number of discrete wavelengths that are required to solve Equations 1-2 are the number of significant absorbers that are present in the solution.


A practical application of this technique is pulse oximetry, which utilizes a noninvasive sensor to measure oxygen saturation (SpO2) and pulse rate. In general, the sensor has light emitting diodes (LEDs) that transmit optical radiation of red and infrared wavelengths into a tissue site and a detector that responds to the intensity of the optical radiation after absorption (e.g., by transmission or transreflectance) by pulsatile arterial blood flowing within the tissue site. Based on this response, a processor determines measurements for SpO2, pulse rate, and can output representative plethysmographic waveforms. Thus, “pulse oximetry” as used herein encompasses its broad ordinary meaning known to one of skill in the art, which includes at least those noninvasive procedures for measuring parameters of circulating blood through spectroscopy. Moreover, “plethysmograph” as used herein (commonly referred to as “photoplethysmograph”), encompasses its broad ordinary meaning known to one of skill in the art, which includes at least data representative of a change in the absorption of particular wavelengths of light as a function of the changes in body tissue resulting from pulsing blood.


Pulse oximeters capable of reading through motion induced noise are available from Masimo Corporation (“Masimo”) of Irvine, Calif. Moreover, portable and other oximeters capable of reading through motion induced noise are disclosed in at least U.S. Pat. Nos. 6,770,028, 6,658,276, 6,157,850, 6,002,952, and 5,769,785. Read which are owned by Masimo, and are incorporated by reference herein. Such reading through motion oximeters have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.


SUMMARY OF THE DISCLOSURE

Despite the success of read through motion oximeter systems, there is a need to provide patient monitors capable of displaying multiple physiological parameters, other than or in addition to SpO2, plethysmograph waveforms, or pulse rates. For example, in accessing a patient's condition, caregivers often desire knowledge of other blood constituents, including for example, a percent value for arterial carbon monoxide saturation (“HbCO”) or a percent value for methemogobin saturation (“HbMet”) or the like. For example, in an embodiment, the display advantageously displays one or more of the following: pulse rate, plethysmograph waveform data, perfusion index, values of blood constituents in body tissue, including for example, HbCO, HbMet, total hemoglobin (“Hbt”), arterial oxygen saturation (“SpO2”), fractional arterial oxygen saturation (“SpaO2”), or the like. In other embodiments, the monitor may advantageously and accurately determine values for one or more of HbO2, Hb, blood glucose, water, the presence or absence of therapeutic drugs (aspirin, Dapson, nitrates, or the like) or abusive/recreational drugs (methamphetamine, alcohol, steroids, or the like), concentrations of carbon dioxide (“CO2”) or oxygen (“O”), ph levels, bilirubin, perfusion quality, signal quality or the like. Accordingly, the present disclosure includes a multi-parameter patient monitor capable of determining one or more of the foregoing parameters, other than or in addition to, SpO2, plethysmograph waveforms, or perfusion quality index.


In an embodiment, the display of a noninvasive multi-parameter patient monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display area or real estate. In an embodiment, a user may cycle different parameter values through an area of the display common to both parameters even when one parameter is shifted, through, for example, actuation of a user input key. The patient monitor may also display different parameters as color-coded. For example, when the following measured parameters are within “normal” ranges, SpO2 may be displayed red, pulse rate (BPM) may be displayed green, HbCO may be displayed orange, HbMet may be displayed blue, or the like. In an embodiment, measured values of SpO2 may be displayed in white, BPM may be displayed in yellow green or aquamarine, PI™ may be displayed in violet, Hbt may be displayed in grass green, HbMet may be displayed in blue or light blue, HbCO may be displayed in orange, and SpaO2 may be displayed in electric blue.


Moreover, parameter trend data may also be displayed using the same or similar color coding, especially when multiple trends are displayed on one or more display graphs. In addition, more coarse or gross parameter indications may be displayed for quick reference to indicate to a caregiver whether any of a variety of monitored parameters, such as, for example, SpO2, HbCO or HbMet is within acceptable ranges. The monitor may advantageously include additional display information, such as, for example, parametric displays where one parameter is displayed as a function of another, three dimensional displays (for example, extending a parametric display along time or an additional parameter), directional indicators predicting where a parameter is likely heading or reporting a general direction a parameters has been trending, or the like.


In addition to the foregoing, caregivers often desire to more closely monitor parameters that are close to, approaching, or beyond normal safe thresholds. In an embodiment, the patient monitor provides an indication that the caregiver should change display modes to view more critical monitored parameters. In alternative embodiments, the patient monitor automatically changes display modes to show parameters moving closer to or beyond normal thresholds.


In an embodiment, the patient monitor includes an audible or visual indication of a type of sensor communicating with the monitor. For example, the monitor may determine how many wavelengths a particular attached sensor will emit through communication with memory devices associated with the attached sensor or cable.


Additional embodiments include audio or visual alarms for each of multiple monitored parameters, combinations of parameters, an indication of perfusion in the tissue of the measurement site, an indication of the confidence the signal processing has in its output measurements, or the like.


In an embodiment, a method of determining which of a plurality of physiological measurements to measure based on the signal quality of the signal is disclosed. The method includes using a sensor configured to measure at least two different physiological measurements to obtain a signal from a light sensitive detector, the sensor including at least three different light emitters emitting at least three different wavelengths of light through tissue of a living patient and detecting the light after attenuation of the tissue, determining a signal quality of the signal, determining which of the at least two different physiological measurements are capable of being measured based on the signal quality determination, and activating only enough of the at least three different light emitters necessary to obtain the measurements capable of being measured.


In an embodiment, if the signal quality is high, all of the at least three different emitters are activated. In an embodiment, if the signal quality is low, only two of the at least three different emitters are activated. In an embodiment, if the signal quality is low, fewer different physiological measurements are measured. In an embodiment, a method of informing a user of a patient monitor about one of a type of sensor communicating with the patient monitor and a type of physiological parameter determinable using the sensor communicating with the patient monitor is disclosed. The method includes receiving information from an information element associated with one of an optical sensor and a communication cable between a patient monitor and an optical sensor, determining a number of wavelengths emitted by the optical sensor from the information, determining a signal quality of a signal received by the optical sensor, and activating an indicator of the type of physiological parameters determinable based on the number wavelengths emitted by the optical sensor and the signal quality of the signal. In an embodiment, the indicator comprises a display of data determined using signals from the optical sensor. In an embodiment, the indicator comprises a visual indicator. In an embodiment, the visual indicator comprises a color. In an embodiment, the visual indicator comprises an LED. In an embodiment, the LED changes color based on which of the first and second sensors is attached. In an embodiment, the LED color comprises red when the first sensor is attached and another color when another sensor is attached. In an embodiment, the indicator comprises an audible indicator. In an embodiment, the audible indictor comprises one or more tones. In an embodiment, the audible indictor emits a first tone when the first sensor is attached and a different second tone when the second sensor is attached.


For purposes of summarization, certain aspects, advantages and novel features are described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features need to be present in any particular embodiment.





BRIEF DESCRIPTION OF THE DRAWINGS

The drawings and the associated descriptions are provided to illustrate embodiments of the disclosure and not to limit the scope of the claims.



FIG. 1 illustrates a block diagram of an exemplary embodiment of a patient monitoring system including a sensor and a multi-parameter patient monitor.



FIG. 2 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor capable of displaying at least HbCO, such as, for example, the patient monitor of FIG. 1.



FIG. 3 illustrates an exemplary display of the patient monitor of FIG. 2.



FIG. 4 illustrates the display of FIG. 3 showing measured values of SpO2, BPM, perfusion, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.



FIG. 5 illustrates the display of FIG. 3 showing measured values of HbCO, perfusion, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.



FIG. 6 illustrates the display of FIG. 3 showing measured values of SpO2, HbCO, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1.



FIG. 7 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor capable of displaying at least HbCO and HbMet, such as, for example, the patient monitor of FIG. 1.



FIG. 8 illustrates an exemplary display of the patient monitor of FIG. 7.



FIG. 9 illustrates the display of FIG. 8 showing measured values of SpO2, BPM, HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.



FIG. 10 illustrates the display of FIG. 8 showing measured values of HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.



FIG. 11A illustrates a perspective view of an exemplary noninvasive multi-parameter patient monitor such as, for example, the patient monitor of FIG. 1.



FIGS. 11B-11H illustrate display screens of the patient monitor of FIG. 11A.





DETAILED DESCRIPTION OF PREFERRED AND ALTERNATIVE EMBODIMENTS

Embodiments of the present disclosure include a portable or other multi-parameter patient monitor capable of determining multiple physiological parameters from one or more signals output from one or more light sensitive detectors capable of detecting light attenuated by body tissue carrying pulsing blood. For example, in an embodiment, the monitor advantageously and accurately determines a wide variety of physiological parameters or other calculations as discussed above.


In an embodiment, the display of patient monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display real estate. For example, the patient monitor may include one or more user input keys capable of toggling through measurement data. In an embodiment, the displays include mode indicators providing caregivers easily identifiable visual queues, such as LED's, text, icons, or other indicia providing readily identifiable queues as to which parameter is being displayed. In an embodiment, the display may shift, may be parameter color-coded, or the like to further ensure quick comprehension of which measured parameter is the displayed parameter. For example, in an embodiment, the monitor displays SpO2 in white, pulse rate (BPM) in green, HbCO in orange, and HbMet in blue when the respective measured parameter is within a “normal” range.


In an embodiment, the patient monitor provides an indication that the caregiver should change display modes to view more critical or time sensitive measured parameters, specific caregiver selected parameters, or the like. For example, the patient monitor may advantageously sound audio or visual alarms that alert the caregiver to particular one or more of worsening parameters, parameters changing in a predetermined pattern or rate, parameters stabilizing below user defined or safe thresholds, caregiver selected parameters, or the like. The monitor may also use alerts that provide audio or visual indications of the severity of the condition, severity of the change, or the like. In alternative embodiments, the patient monitor may automatically change display modes when a particular parameter crosses one or more thresholds. For example, a patient monitor may be displaying a first parameter, such as a plethysmograph, and upon determining measurements indicating that HBMet is trending toward an alarm condition, the monitor may automatically switch from displaying the first parameter to the alarming parameter, or in this case, a trend of the alarming parameter.


In an embodiment, a switch is provided to allow a user to switch displays to view an alarming measurement. In an embodiment, during an alarm condition, a parameter display may switch to a trend graph in the same or different color, line weight, flash, flash rate, intensity, size, or the like.


The patient monitor may also include one or more displays capable of displaying trend data for any one or more of the monitored or derived patient parameters. For example, the trend data may be displayed in graph form, may include multiple trend lines, each representing a different monitored or derived patient parameter. Moreover, each trend line may be color-coded to facilitate quick comprehension of which trend line represents which measured parameter. However, an artisan will recognize from the disclosure herein a large number of identification techniques including color-coding, identifying text, or the like. Additionally, user input may toggle displayed trend data, may select which parameters to display simultaneously, or the like.


In an embodiment, the patient monitor includes an audible or visual indication of a type of sensor communicating with the monitor. For example, the patient monitor may provide a particular audio or visual indication, such as a beep, LED activation, graphic activation, text messages, voice messages, or the like, to indicate communication with or connection to an approved sensor, patient cable, combination, or the like. In an embodiment, the indication may change based on the manufacturer, type of sensor recognized or not recognized, type of patient, type of physiological parameters measurable with the attached sensor, or the like. Additional embodiments include an indication of perfusion in the tissue of the measurement site and an indication of the confidence the signal processing has in its output measurements or input signal quality.


To facilitate an understanding of the disclosure, the remainder of the description references exemplary embodiments illustrated in the drawings. Moreover, in this application, reference is made to many blood parameters. Some references that have common shorthand designations are referenced through such shorthand designations. For example, as used herein, HbCO designates carboxyhemoglobin, HbMet designates methemoglobin, and Hbt designates total hemoglobin. Other shorthand designations such as COHb, MetHb, and tHb are also common in the art for these same constituents. These constituents are generally reported herein in terms of a percentage, often referred to as saturation, relative concentration or fractional saturation. Total hemoglobin is generally reported as a concentration in g/dL. The use of the particular shorthand designators presented in this application does not restrict the term to any particular manner in which the designated constituent is reported.



FIG. 1 illustrates a block diagram of an exemplary embodiment of a patient monitoring system 100. As shown in FIG. 1, the system 100 includes a patient monitor 102 comprising a processing board 104 and a host instrument 108. The processing board 104 communicates with a sensor 106 to receive one or more intensity signal(s) indicative of one or more parameters of tissue of a patient. The processing board 104 also communicates with a host instrument 108 to display determined values calculated using the one or more intensity signals. According to an embodiment, the board 104 comprises processing circuitry arranged on one or more printed circuit boards capable of installation into the monitor 102, or capable of being distributed as some or all of one or more OEM components for a wide variety of host instruments monitoring a wide variety of patient information. In an embodiment, the processing board 102 comprises a sensor interface 110, a digital signal processor and signal extractor (“DSP” or “processor”) 112, and an instrument manager 114. In general, the sensor interface 110 converts digital control signals into analog drive signals capable of driving sensor emitters, and converts composite analog intensity signal(s) from light sensitive detectors into digital data.


In an embodiment, the sensor interface 110 manages communication with external computing devices. For example, in an embodiment, a multipurpose sensor port (or input/output port) is capable of connecting to the sensor 106 or alternatively connecting to a computing device, such as a personal computer, a PDA, additional monitoring equipment or networks, or the like. When connected to the computing device, the processing board 104 may upload various stored data for, for example, off-line analysis and diagnosis. The stored data may comprise trend data for any one or more of the measured parameter data, plethysmograph waveform data acoustic sound waveform, or the like. Moreover, the processing board 104 may advantageously download from the computing device various upgrades or executable programs, may perform diagnosis on the hardware or software of the monitor 102. In addition, the processing board 104 may advantageously be used to view and examine patient data, including raw data, at or away from a monitoring site, through data uploads/downloads, or network connections, combinations, or the like, such as for customer support purposes including software maintenance, customer technical support, and the like. Upgradable sensor ports are disclosed in copending U.S. application Ser. No. 10/898,680, filed on Jul. 23, 2004, titled “Multipurpose Sensor Port,” incorporated by reference herein.


As shown in FIG. 1, the digital data is output to the DSP 112. According to an embodiment, the DSP 112 comprises a processing device based on the Super Harvard ARChitecture (“SHARC”), such as those commercially available from Analog Devices. However, a skilled artisan will recognize from the disclosure herein that the DSP 112 can comprise a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In particular, the DSP 112 includes program instructions capable of receiving multiple channels of data related to one or more intensity signals representative of the absorption (from transmissive or reflective sensor systems) of a plurality of wavelengths of emitted light by body tissue. In an embodiment, the DSP 112 accepts data related to the absorption of eight (8) wavelengths of light, although an artisan will recognize from the disclosure herein that the data can be related to the absorption of two (2) to sixteen (16) or more wavelengths.



FIG. 1 also shows the processing board 104 including the instrument manager 114. According to an embodiment, the instrument manager 114 may comprise one or more microcontrollers controlling system management, including, for example, communications of calculated parameter data and the like to the host instrument 108. The instrument manager 114 may also act as a watchdog circuit by, for example, monitoring the activity of the DSP 112 and resetting it when appropriate.


The sensor 106 may comprise a reusable clip-type sensor, a disposable adhesive-type sensor, a combination sensor having reusable and disposable components, or the like. Moreover, an artisan will recognize from the disclosure herein that the sensor 106 can also comprise mechanical structures, adhesive or other tape structures, Velcro wraps or combination structures specialized for the type of patient, type of monitoring, type of monitor, or the like. In an embodiment, the sensor 106 provides data to the board 104 and vice versa through, for example, a patient cable. An artisan will also recognize from the disclosure herein that such communication can be wireless, over public or private networks or computing systems or devices, or the like.


As shown in FIG. 1, the sensor 106 includes a plurality of emitters 116 irradiating the body tissue 118 with differing wavelengths of light, and one or more detectors 120 capable of detecting the light after attenuation by the tissue 118. In an embodiment, the emitters 116 comprise a matrix of eight (8) emission devices mounted on a flexible substrate, the emission devices being capable of emitting eight (8) differing wavelengths of light. In other embodiments, the emitters 116 may comprise twelve (12) or sixteen (16) emitters, although other numbers of emitters are contemplated, including two (2) or more emitters. As shown in FIG. 1, the sensor 106 may include other electrical components such as, for example, a memory device 122 comprising an EPROM, EEPROM, ROM, RAM, microcontroller, combinations of the same, or the like. In an embodiment, other sensor components may include a temperature determination device 123 or other mechanisms for, for example, determining real-time emission wavelengths of the emitters 116.


The memory 122 may advantageous store some or all of a wide variety data and information, including, for example, information on the type or operation of the sensor 106; type or identification of sensor buyer or distributor or groups of buyer or distributors, sensor manufacturer information, sensor characteristics including the number of emitting devices, the number of emission wavelengths, data relating to emission centroids, data relating to a change in emission characteristics based on varying temperature, history of the sensor temperature, current, or voltage, emitter specifications, emitter drive requirements, demodulation data, calculation mode data, the parameters for which the sensor is capable of supplying sufficient measurement data (e.g., HpCO, HpMet, HbT, or the like), calibration or parameter coefficient data, software such as scripts, executable code, or the like, sensor electronic elements, whether the sensor is a disposable, reusable, multi-site, partially reusable, partially disposable sensor, whether it is an adhesive or non-adhesive sensor, whether the sensor is a reflectance, transmittance, or transreflectance sensor, whether the sensor is a finger, hand, foot, forehead, or ear sensor, whether the sensor is a stereo sensor or a two-headed sensor, sensor life data indicating whether some or all sensor components have expired and should be replaced, encryption information, keys, indexes to keys or hash functions, or the like, monitor or algorithm upgrade instructions or data, some or all of parameter equations, information about the patient, age, sex, medications, and other information that may be useful for the accuracy or alarm settings and sensitivities, trend history, alarm history, or the like. In an embodiment, the monitor may advantageously store data on the memory device, including, for example, measured trending data for any number of parameters for any number of patients, or the like, sensor use or expiration calculations, sensor history, or the like.



FIG. 1 also shows the patient monitor 102 including the host instrument 108. In an embodiment, the host instrument 108 communicates with the board 104 to receive signals indicative of the physiological parameter information calculated by the DSP 112. The host instrument 108 preferably includes one or more display devices 124 capable of displaying indicia representative of the calculated physiological parameters of the tissue 118 at the measurement site. In an embodiment, the host instrument 108 may advantageously comprise a handheld housing capable of displaying one or more of a pulse rate, plethysmograph data, perfusion quality such as a perfusion quality index (“PI™”), signal or measurement quality (“SQ”), values of blood constituents in body tissue, including for example, SpO2, HbCO, HbMet, Hbt, or the like. In other embodiments, the host instrument 108 is capable of displaying values for one or more of Hbt, Hb, blood glucose, bilirubin, or the like. The host instrument 108 may be capable of storing or displaying historical or trending data related to one or more of the measured values, combinations of the measured values, plethysmograph data, or the like. The host instrument 108 also includes an audio indicator 126 and user input device 128, such as, for example, a keypad, touch screen, pointing device, voice recognition device, or the like.


In still additional embodiments, the host instrument 108 includes audio or visual alarms that alert caregivers that one or more physiological parameters are falling below predetermined safe thresholds. The host instrument 108 may include indications of the confidence a caregiver should have in the displayed data. In a further embodiment, the host instrument 108 may advantageously include circuitry capable of determining the expiration or overuse of components of the sensor 106, including, for example, reusable elements, disposable elements, or combinations of the same.


Although described in terms of certain embodiments, other embodiments or combination of embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, the monitor 102 may comprise one or more monitoring systems monitoring parameters, such as, for example, vital signs, blood pressure, ECG or EKG, respiration, glucose, bilirubin, or the like. Such systems may combine other information with intensity-derived information to influence diagnosis or device operation. Moreover, the monitor 102 may advantageously include an audio system, preferably comprising a high quality audio processor and high quality speakers to provide for voiced alarms, messaging, or the like. In an embodiment, the monitor 102 may advantageously include an audio out jack, conventional audio jacks, headphone jacks, or the like, such that any of the display information disclosed herein may be audiblized for a listener. For example, the monitor 102 may include an audible transducer input (such as a microphone, piezoelectric sensor, or the like) for collecting one or more of heart sounds, lung sounds, trachea sounds, or other body sounds and such sounds may be reproduced through the audio system and output from the monitor 102. Also, wired or wireless communications (such as Bluetooth or WiFi, including IEEE 801.11a, b, or g), mobile communications, combinations of the same, or the like, may be used to transmit the audio output to other audio transducers separate from the monitor 102.


For example, patterns or changes in the continuous noninvasive monitoring of intensity-derived information may cause the activation of other vital sign measurement devices, such as, for example, blood pressure cuffs.



FIG. 2 illustrates a perspective view of an exemplary handheld noninvasive multi-parameter patient monitor 200, such as, for example, the patient monitor 102 of FIG. 2. Patient monitors 200 exhibiting combinations of many of the features described herein are advantageously commercially available from Masimo under the brand name “Rad 57c.” As shown in FIG. 1, the monitor 200 includes a patient cable connector 202 capable of mechanical mating with a patient cable to establish communication between the board 104 and the sensor 106. In an embodiment, the connector 202 comprises a multipurpose cable connector such as that disclosed in the incorporated U.S. application Ser. No. 10/898,680, titled “Multipurpose Sensor Port,” disclosing communication between the board 104 and an external computing device.


The monitor 200 also comprises a HbCO indicator 204 advantageously providing a visual queue that a HbCO capable sensor is properly connected through the connector 202. For example, the HbCO indicator 204 may advantageously activate when a sensor is connected that communicates sufficient information to determine HbCO, such as, for example, a sensor capable of emitting sufficient different wavelengths of light, a sensor storing sufficient data on the memory 122, a sensor having appropriate encryption data or key, combinations of the same, or the like. For example, in an embodiment, the processor 112 may receive information from a memory 122 indicating a number of available LED wavelengths for the attached sensor. Based on the number of wavelengths, or other information stored on the memory 122, the processor 112 may determine whether an HbCO-ready sensor has been attached to the monitor 200. An artisan will also recognize from the disclosure herein that the HbCO indicator 204 may advantageously comprise a HbMet indicator, Hbt indicator, or the like, which activates to a predetermined color associated with a parameter, or any color, or deactivates the same, to convey a type of attached sensor. Moreover, the artisan will recognize from the disclosure herein other parameters that may use other sensor components and the monitor 200 may include indicators capable of indicating communication with those types of sensors.


In an embodiment, the monitor 200 may also audibly indicate the type of sensor connected. For example, the monitor 200 may emit predetermined number or frequency of beeps associated with recognition of a particular sensor, a particular manufacturer, failure to recognize the sensor, or the like. Moreover, the sensor type may be indicative of the componentry, such as, for example, whether the sensor produces sufficient data for the determination of HbCO, HbMet, Hbt and SpO2, SpO2 only, SpO2 and HbMet, any combination of the foregoing or other parameters, or the like. Additionally, the sensor type may be indicative of specific sensors designed for a type of patient, type of patient tissue, or the like. In other embodiments, the monitor 200 may announce the type of connector through speaker 236.


An artisan will also recognize from the disclosure herein that other mechanical (such as keys), electrical, or combination devices may inform the monitor 202 of the type of attached sensor. In an embodiment, the processor 112 also may select to drive less emitters that are currently available, such as, for example, in the presence of low noise and when power consumption is an issue.


The monitor 200 also comprises a multi-mode display 206 capable of displaying, for example, measurements of SpO2 and HbCO (or alternatively, HbMet). In an embodiment, the display 206 has insufficient space or display real estate to display the many parameters capable of being measured by the monitor 200. Thus, the multi-mode display 206 may advantageously cycle through two or more measured parameters in an area common to both parameters even when shifted. In such embodiments, the monitor 200 may also advantageously include parameter indicators 208, 210, providing additional visual queues as to which parameter is currently displayed. In an embodiment, the display may also cycle colors, flash rates, or other audio or visual queues providing readily identifiable information as to which measured parameter is displayed. For example, when the multi-mode display 206 displays measured values of SpO2 that are normal, the numbers may advantageously appear in green, while normal measured values of HbCO may advantageously appear in orange, and normal measured values of HbMet may appear in blue. Moreover, in an embodiment, the display 206 flashes at a predefined rate when searching for saturation and at another predefined rate when a signal quality is below a predetermined threshold.


The monitor 200 also comprises a HbCO bar 212 where in an embodiment a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value. For example, the bar 212 is lowest when the dangers from carbon monoxide poisoning are the least, and highest when the dangers are the greatest. The bar 212 includes indicia 214 that provide an indication of the severity of carbon monoxide saturation in a patient's blood. As shown in FIG. 2, the bar 212 and the indicia 214 continuously indicate the concentration of HbCO in about 5% increments. The indicia 214 indicate a measurement of HbCO saturation percentage between about 0 and about 50% with a granularity of about 5%. However, an artisan will also recognize from the disclosure herein a wide variety of ranges and granularities could be used, the indicia 214 could be electronically displayed in order to straightforwardly increase or decrease resolution, or the like. For example, HbCO may advantageously be displayed with greater resolution than ±about %5 in a lower portion of the scale. For example, an HbCO bar may advantageously include a scale of about <3%, about 6%, about 9%, about 12%, about 15%, about 20%, about 25%, about 30%, about 35%, and about >40%.


As is known in the art, carbon monoxide in the blood can lead to serious medical issues. For example and depending upon the particular physiology of a patient, about 10% carbon monoxide saturation can lead to headaches, about 20% can lead to throbbing headaches, or dyspnea on exertion, about 30% can lead to impaired judgment, nausea, dizziness and/or vomiting, visual disturbance, or fatigue, about 40% can lead to confusion and syncope, and about 50% and above can lead to comas, seizures, respiratory failure and even death.


In an embodiment, the bar 212 is the same or similar color as the multi-mode display 206 when displaying HbCO. In other embodiments, the bar 212 is lowest and green when the dangers from carbon monoxide poisoning are the least, and highest and red when the dangers are the greatest. In an embodiment, as HbCO increases, the entire bar 212 may advantageously change color, such as, for example, from green to red, to provide a clear indication of deepening severity of the condition. In other embodiments, the bar 212 may advantageously blink or flash, an audio alarm may beep or provide a continuation or rise in pitch or volume, or the like to alert a caregiver of deepening severity. Moreover, straightforward to complex alarm rules may be implemented to reduce false alarms based on, for example, knowledge of the physiological limitations on the rate of change in HbCO or the like.


Additionally, the monitor 200 may be capable of storing and outputting historical parameter data, display trend traces or data, or the like. Although the foregoing bar 212 has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein.



FIG. 2 also shows the monitor 200 including a pulse display 216 displaying measured pulse rate in beats per minute (“BPM”). In an embodiment, the display 212 flashes when searching for a pulse. The pulse display 216 advantageously displays measured pulse rates from about zero (0) to about two hundred and forty (240) BPM. Moreover, when the measured pulse rates are considered normal, the pulse display 216 is advantageously green. Similar to other displays associated with the monitor 200, the pulse display 216 may employ a variety of color changes, audio alarms, or combinations of the same to indicate measured BPM below predetermined safe thresholds. In an embodiment, the pulse rate display 216 displays the measured pulse rate during the display of SpO2 and displays message data during the display of other parameters. For example, during the display of HbCO, the display 216 may advantageously display the term “CO.” In an embodiment, the display of the message data may be in the same or similar color as the other displays. For example, in an embodiment, the multi-mode display 206, the bar 212, and the pulse display 216 may all display data or messages in orange when the multi-mode display 206 displays measured HbCO values.



FIG. 2 also illustrates the monitor 200 comprising user input keys 218, including a HbCO button 220, mode/enter button 222, next button 224, power on/off button 226, up/down button 228, and alarm silence button 230. In an embodiment, activation of the HbCO button 220 toggles the measured value displayed in the multi-mode display 206. For example, activation of the HbCO button 220 toggles the multi-mode display 206 from displaying measured values of SpO2 to HbCO for about ten (10) seconds. Activation of the mode/enter button 222 or the next button 224 during the ten (10) second period returns the multi-mode display 206 back to SpO2. A skilled artisan will also recognize that activation of the HbCO button 220 may advantageously toggle through a plurality of measured values, and that such values may be displayed for short segments and then return to SpO2, may remain displayed until further activation of the button 220, or the like.


Activation of the mode/enter button 222 cycles through various setup menus allowing a caregiver to select or activate certain entries within the menu setup system, including alarm threshold customizations, or the like. Activation of the next button 224 can move through setup options within the menu setup system and in an embodiment is not active during normal patient monitoring. For example, a caregiver may activate the mode/enter button 222 and the next button 224 to specify high and low alarm thresholds for one or more of the measured parameters, to specify device sensitivity, trend settings, display customizations, color code parameters, or the like. In an embodiment, the high alarm setting for SpO2 can range from about two percent (2%) to about one hundred percent (100%) with a granularity of about one percent (1%). The low alarm setting for SpO2 can range from about one percent (1%) to about one hundred percent (100%) with a granularity of about one percent (1%). Moreover, the high alarm setting for pulse rate can range from about thirty (30) BPM to about two hundred and forty (240) BPM with a granularity of about five (5) BPM. The low alarm setting for pulse rate can range from about twenty five (25) BPM to about two hundred and thirty five (235) BPM with a granularity of about five (5) BPM. Other high and low ranges for other measured parameters will be apparent to one of ordinary skill in the art from the disclosure herein.


In a further embodiment, a caregiver may activate the mode/enter button 222 and the next button 224 to specify device sensitivity, such as, for example, device averaging times, probe off detection, whether to enable fast saturation calculations, or the like. Various embodiments of fast saturation calculations are disclosed in U.S. patent application Ser. No. 10/213,270, filed Aug. 5, 2002, titled “Variable Indication Estimator” and incorporated by reference herein. Using the menus, a caregiver may also advantageously enter appropriate information governing trend collection on one or more of the measured parameters, input signals, or the like.



FIG. 2 also shows the power on/off button 226. Activation of the power on/off button 226 activates and deactivates the monitor 200. In an embodiment, press-and-hold activation for about two (2) seconds shuts the monitor 200 off. In an additional embodiment, activation of the on/off button 226 advantageously initiates detection of a type of attached sensor. For example, activation of the on/off button 226 may advantageously cause the monitor 200 to read information from a memory on an attached sensor and determine whether sufficient wavelengths exist on the sensor to determine one or more the physiological parameters discussed in the foregoing.


An artisan will recognize from the disclosure herein that the on/off button 226 may advantageously cause an electronic determination of whether to operate in at powers consisted with the U.S. (60 Hz) or another nationality (50 Hz). In an embodiment, such automatic determination and switching is removed from the monitor 200 in order to reduce a likelihood of problematic interfering crosstalk caused by such power switching devices.


Activation of the up/down button 228 may advantageously adjust the volume of the pulse beep tone. Additionally, activation of the up/down button 228 within the menu setup system, causes the selection of values with various menu options.


Moreover, activation of the alarm silence button 230 temporarily silences audio alarms for a predetermined period, such as, for example, about one hundred and twenty (120) seconds. A second activation of the alarm silence button 230 mutes (suspends) the alarm indefinitely, while a third activation returns the monitor 200 to standard alarm monitoring. FIG. 2 also shows the alarm silence button 230 includes an alarm silenced indicator 232. The alarm silenced indicator 232 may advantageously flash to indicate one or more alarms are temporarily silenced, may illuminate solid to indicate the alarms have been muted, or the like. Moreover, an artisan will recognize from the disclosure herein a wide variety of alarm silencing methodologies.


The monitor 200 also includes a battery level indicator 234 indicating remaining battery life. In the illustrated embodiment, four LED's indicate the status of the battery by incrementally deactivating to indicate proportionally decreasing battery life. In an embodiment, the four LED's may also change color as the battery charge decreases, and the final LED may begin to flash to indicate that the caregiver should replace the batteries.



FIG. 2 also shows the monitor 200 including an audio transducer or speaker 236. The speaker 236 advantageously provides audible indications of alarm conditions, pulse tone and feedback for key-presses, or the like. Moreover, the monitor 202 includes a low signal quality indicator (“SQ” or “SIQ™”) 238. The signal IQ indicator 238 activates to inform a caregiver that a measured value of the quality of the incoming signal is below predetermined threshold values. For example, in an embodiment, the measured value for signal IQ is at least partially based on an evaluation of the plethysmograph data's correspondence to predetermined models or characteristics of physiological signals. In an embodiment, the signal IQ indicator 238 output may be associated with the displayed parameter. For example, the output may be associated with one threshold for the display of SpO2 and another for the display of other parameter data.


The monitor 200 also comprises a perfusion quality index (“PI™”) bar 240 (which quantifies the measure of perfusion of the patient) where in an embodiment a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value. In one embodiment, the PI™ bar 240 shows a static value of perfusion for a given time period, such as, for example, one or more pulses. In another embodiment, or functional setting, the PI™ bar 240 may advantageously pulse with a pulse rate, may hold the last reading and optionally fade until the next reading, may indicate historical readings through colors or fades, or the like. Additionally, the PI™ bar 240 may advantageously change colors, flash, increasingly flash, or the like to indicate worsening measured values of perfusion.


The PI™ bar 240 can be used to simply indicate inappropriate occlusion due, for example, to improper attachment of the sensor 106. The PI™ bar 240 can also be used as a diagnostic tool during low perfusion for the accurate prediction of illness severity, especially in neonates. Moreover, the rate of change in the PI™ bar 240 can be indicative of blood loss, sleep arousal, sever hypertension, pain management, the presence or absence of drugs, or the like. According to one embodiment, the PI™ bar 240 values may comprise a measurement of the signal strength of the arterial pulse as a percentage of the total signal received. For example, in one preferred embodiment, the alternating portion of at least one intensity signal from the sensor 106 may advantageously be divided by the static portion of the signal. For example, an infrared intensity signal may advantageously be used as it is less subjective to noise.


In an embodiment, a measurement below about 1.25% may indicate medical situations in need of caregiver attention, specifically in monitored neonates. Because of the relevance of about 1.25%, the PI™ bar 240 may advantageously include level indicia 242 where the indicia 242 swap sides of the PI™ bar 240, thus highlighting any readings below about that threshold. Moreover, behavior of the PI™ bar 240, as discussed above, may advantageously draw attention to monitored values below such a threshold.


As discussed above, the monitor 200 may include output functionality that outputs, for example, trend perfusion data, such that a caregiver can monitor measured values of perfusion over time. Alternatively or additionally, the monitor 200 may display historical trace data on an appropriate display indicating the measured values of perfusion over time. In an embodiment, the trend data is uploaded to an external computing device through, for example, the multipurpose sensor connector 202 or other input output systems such as USB, serial or parallel ports or the like.


The monitor 200 also includes an alarm indicator 244 capable of providing visual queues of the status of one or more of the measured parameters. For example, the alarm indicator 244 may advantageously be green when all of the measured parameters are within normal conditions, may gradually fade to red, may flash, increasing flash, or the like, as one or more of the measured values approaches or passes predetermined thresholds. In an embodiment, the alarm indicator 244 activates when any parameter falls below an associated threshold, thereby advantageously informing a caregiver that perhaps a nondisplayed parameters is at an alarm condition. In another embodiment, the alarm indicator 244 may indicate the status of the parameter displayed on the multi-mode display 206. In an embodiment, the speaker 236 may sound in conjunction with and/or in addition to the indicator 244. Moreover, in an embodiment, an alarming parameter may automatically be displayed, may be emphasized, flashed, colored, combinations of the same or the like to draw a user's attention to the alarming parameter.


Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein.



FIG. 3 illustrates an exemplary display of the patient monitor 200. As shown in FIG. 3, the display includes the multi-mode display 206, the pulse rate display 216, parameter indicators 208, 210, the HbCO bar 212 and indicator 204, the PI™ bar 240, and the alarm indicator 244. In an embodiment, the multi-mode display 206 and the pulse rate display 216 each comprise a plurality of seven segment displays 302 capable of displaying alpha-numeric information. As disclosed in the foregoing, the exemplary display may advantageously include color-coded parameter displays. Moreover, the exemplary display may include color progressions, flashing, flashing progressions, audible alarms, audible progressions, or the like, indicating worsening measured values of physiological data. In addition, in an embodiment, some or all of the displays may flash at a first rate to indicate attempts to acquire data when actual measured values are unavailable. Moreover, some or all of the display may flash at a second rate to indicate low signal quality where confidence is decreasing that the measured values reflect actual physiological conditions.



FIG. 4 illustrates the display of FIG. 3 showing measured values of SpO2, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1. As shown in FIG. 4, the multi-mode display 206 is displaying a percentage value of SpO2, and the pulse rate display 216 is displaying a pulse rate in beats per minute. Accordingly, the parameter indicator 210 is activated to confirm the display of measured values of SpO2. As disclosed in the foregoing, in an embodiment, the multi-mode display 206 is red, indicating blood oxygen measurements while the pulse rate display 216 is green, indicating normal values of a patient's pulse.



FIG. 4 also shows the PI™ bar 240 almost fully activated, representing good perfusion. In addition, the HbCO indicator 204 is showing communication with a sensor producing insufficient data to determine measured values of additional parameters, such as, HbCO. In an embodiment, such sensors may comprise sensors capable of emitting light at about two (2) different wavelengths, may comprise sensors with insufficient data stored on a memory associated therewith, or the like.



FIG. 5 illustrates the display of FIG. 3 showing measured values of HbCO, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1. As shown in FIG. 5, the multi-mode display 206 is displaying a percentage value of HbCO, and the pulse rate display 216 is displaying an appropriate message indicating the HbCO measurement, such as, for example, “CO”. Also, the multi-mode display 206 has shifted the data to the left to quickly and efficiently indicate that the displayed parameter is other than SpO2. Accordingly, the parameter indicator 208 is also activated to confirm the display of measured values of HbCO. As disclosed in the foregoing, in an embodiment, the multi-mode display 206 and pulse rate display message 216 are orange.



FIG. 5 also shows the PI™ bar 240 almost fully activated, representing good perfusion. In addition, the activation of the HbCO indicator 204 represents communication with a sensor capable of producing sufficient data to determine measured values of HbCO. In an embodiment, such sensors may comprise sensors capable of emitting light at about eight (8) or more different wavelengths; however, such sensors may comprise about two (2) or more different wavelengths. Moreover, such sensors may have appropriate data stored on a memory associated therewith, or the like. FIG. 5 also shows the HbCO measurement being about 20% (as illustrated on the HbCO bar 212 and multi-mode display 206) thereby indicating a potentially dangerous situation that if exacerbated, will become quite problematic. Therefore, the alarm indicator 244 is also activated, and in some embodiments, the speaker 236 as well.



FIG. 6 illustrates the display of FIG. 3 showing measured values of SpO2, HbCO, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1. In contrast to FIG. 4, FIG. 6 shows that the monitor 200 is communicating with a sensor capable of producing sufficient data to determine measured values of HbCO, even though the displayed values are that of SpO2 and BPM. Thus, FIG. 6 shows the activation of the HbCO indicator 204, and the continuous monitoring of HbCO by the HbCO bar 212. FIG. 6 also shows a high value of HbCO, and therefore, the indication of an alarm condition by activation of the alarm indicator 244. In an embodiment, upon determination of an alarm condition on a nondisplayed parameter, the monitor 200 may advantageously provide an alarm indication through speaker and alarm indicator activation, automatic toggle to the nondisplayed parameter on the multi-mode display 206 for a defined or undefined time, or the like.



FIG. 7 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor 700 capable of displaying at least HbCO and HbMet, such as, for example, the patient monitor of FIG. 1. Patient monitors exhibiting combinations of many of the features described herein are advantageously commercially available from Masimo under the brand name “Rad 57 cm.” As shown in FIG. 7, the monitor 700 comprises a monitor similar to monitor 200 disclosed with reference to FIG. 2. Moreover, monitor 700 further includes a multi-mode display 706 capable of displaying, for example, measurements of HbMet and BPM. In an embodiment, the display 706 has insufficient space or display real estate to display the many parameters capable of being measured by the monitor 700. Thus, the multi-mode display 706 may advantageously cycle through two or more measured parameters. In such embodiments, the monitor 700 may also advantageously include parameter indicators 708, 710, providing additional visual queues as to which parameter is currently displayed. In an embodiment, the display 706 may also cycle colors, flash rates, or other audio or visual queues providing readily identifiable information as to which measured parameter is displayed. For example, when the multi-mode display 706 displays measured values of BPM that are normal, the numbers may advantageously appear in green, while normal measured values of HbMet may appear in blue. Moreover, in an embodiment, the display 706 may flash at a predefined rate when searching for saturation and at another predefined rate when a signal quality is below a predetermined threshold.



FIG. 7 also illustrates the monitor 700 comprising user input keys 718, including an HbCO/HbMet button 220. In an embodiment, activation of the HbCO/HbMet button 720 toggles the measured value displayed in the multi-mode display 706. For example, activation of the HbCO/HbMet button 720 toggles the multi-mode display 206 from displaying measured values of SpO2 and BPM, to HbCO and HbMet for about ten (10) seconds. Activation of the mode/enter button 222 or the next button 224 during the ten (10) second period returns the multi-mode display 706 back to SpO2 and BPM. A skilled artisan will also recognize that activation of the HbCO/HbMet button 720 may advantageously toggle through a plurality of measured values, and that such values may be displayed for short segments and then return to SpO2 and BPM, may remain displayed until further activation of the button 720, or the like.


The monitor 700 also comprises a coarser indication of HbMet through an HbMet bar 740. In an embodiment, a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value, with increments at about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 7.5%, about 10%, about 15% and greater than about 20%, although an artisan will recognize from the disclosure herein other useful delineations. Additionally, the HbMet bar 740 may advantageously change colors, flash, increasingly flash, or the like to indicate worsening measured values of perfusion.


Although disclosed with reference to the HbMet bar 740, and artisan will recognize from the disclosure herein other coarse or even gross indications of HbMet, or any measured parameter. For example, a single LED may advantageously show green, yellow, and red, to indicate worsening coarse values of HbMet. Alternatively, a single LED may simply light to indicate an alarm or approaching alarm condition.



FIG. 8 illustrates an exemplary display of the patient monitor 700 of FIG. 7. As shown in FIG. 8, the display includes the multi-mode displays 206, 706, parameter indicators 208, 210, 708, 710, the HbCO bar 212 and indicator 204, the HbMet bar 740, and the alarm indicator 244. In an embodiment, the multi-mode display 706 is similar to multi-mode display 206, comprising a plurality of seven segment displays 302 capable of displaying alpha-numeric information, and capable of altering its display characteristics or aspects in a wide variety of configurations discussed with reference to the display 206.



FIG. 9 illustrates the display of FIG. 8 showing measured values of SpO2, BPM, HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1. FIG. 9 also shows the HbMet bar 740 near the bottom and corresponding to about 1%, representing acceptable HbMet, while the HbCO bar 212 hovers at a dangerous near 20%. In addition, the HbCO indicator 204 is showing communication with a sensor producing sufficient data to determine measured values of additional parameters, such as, HbMet, HbCO or the like. In an embodiment, such sensors may comprise sensors capable of emitting light of more than two (2) different wavelengths, preferably more than four (4) different wavelengths, and more preferably eight (8) or more different wavelengths.



FIG. 10 illustrates the display of FIG. 8 showing measured values of HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1. As shown in FIG. 10, the multi-mode display 706 is displaying a percentage value of HbMet that is shifted using the parameter indicator 708. The data has been advantageously shifted to the left to quickly and efficiently indicate that the displayed parameter is other than BPM. Accordingly, the parameter indicator 708 is also activated to confirm the display of measured values of HbMet. As disclosed in the foregoing, in an embodiment, the multi-mode display 706 is blue.



FIG. 10 also shows the HbMet bar 740 nearly empty, representing acceptable HbMet. In addition, the activation of the HbCO indicator 204 represents communication with a sensor capable of producing sufficient data to determine measured values of HbCO. In an embodiment, such sensors may have appropriate data stored on a memory associated therewith, or the like. FIG. 10 also shows the HbCO measurement being about 20% (as illustrated on the HbCO bar 212 and multi-mode display 206) thereby indicating a potentially dangerous situation that if exacerbated, will become quite problematic. Therefore, the alarm indicator 244 is also activated, and in some embodiments, the speaker 236 as well.



FIG. 11A illustrates a perspective view of an exemplary noninvasive multi-parameter patient monitor 1000, such as, for example, the patient monitor of FIG. 1. Moreover, FIGS. 11B-11E illustrate exemplary display screens of the patient monitor of FIG. 11A. As shown in FIGS. 11A-11B, an embodiment of the monitor 1000 includes a display 1101 showing a plurality of parameter data. For example, the display may advantageously comprise a CRT or an LCD display including circuitry similar to that available on oximeters commercially available from Masimo Corporation of Irvine, Calif. sold under the name Radical™, and disclosed in the U.S. patents referenced above and incorporated above. However, an artisan will recognize from the disclosure herein many commercially available display components capable of displaying multiple parameter data along with the ability to display graphical data such as plethysmographs, trend traces, and the like.


In an embodiment, the display includes a measured value of SpO2 1102, a measured value of pulse rate 1104 in BPM, a plethysmograph 1106, a measured value of HbCO 1108, a measured value of HbMet 1110, a measured value of a perfusion quality 1112, a measured value of Hbt 1114, and a derived value of fractional saturation “SpaO2116. In an embodiment, SpaO2 comprises HbO2 expressed as a percentage of the four main hemoglobin species, i.e., HbO2, Hb, HbCO, and HbMet.


In an embodiment, one or more of the foregoing parameter includes trending or prediction indicators 1118 showing the current trend or prediction for that corresponding parameter. In an embodiment, the indicators 1118 may advantageously comprise an up arrow, a down arrow, and a hyphen bar to indicate up trending/prediction, down trending/prediction, or neutral trending/prediction.



FIG. 11C illustrates an exemplary display screen showing trend graph 1140 including trend line 1142 for HbMet. In an embodiment, the trend line 1142 may be advantageously colored for quick straightforward recognition of the trending parameter, may be associated with any one or more of the foregoing alarm attributes, may include trending lines for other parameters, or the like. The display screen also shows trending directional indicators 1142, 1144 for many of the displayed physiological parameters. In an embodiment, the directional indicators 1142, 1144 may advantageously comprises arrows showing the recent trend, predicted trend, user-customizable trend, combinations thereof, or the like for the associated parameters. In an embodiment, the directional indicators 1142, 1144 comprises an up arrow indicating a rising trend/predicted trend, a middle bar indicating a somewhat stable trend/predicted trend, and a down arrow indicating a lowering trend/predicted trend. An artisan will recognize a wide variety of other directional indicators 1142, 1144 from the disclosure herein.



FIG. 11D shows an exemplary display screen in vertical format. Such vertical format could be user actuated or based on a gravity switch. FIGS. 11E-11F illustrate additional displays of various physiological parameters similar to those discussed in the foregoing. being As shown in FIG. 11G, the display includes a measured value of SpO2 1162, a measured value of pulse rate 1164 in BPM, a plethysmograph 1166, a HbCO bar 1168, and a HbMet bar 1170. In an embodiment, the HbCO bar 1168 and HbMet bar 1170 may advantageously behave the same or similarly to the HbCO bar 212 and HbMet bar 712. Moreover, similar bars may advantageously display any of the physiological parameters discussed herein using display indicia appropriate to that parameter. For example, a SpO2 or SpaO2 bar may advantageously range from about 0% to about 100%, and more preferably range from about 50% to about 100%, while a Hbt bar may advantageously range from about 0 to about 30.


Moreover, similar to the disclosure above, the measured value of SpO2 1162 may advantageously toggle to measured values of HbCO, HbMet, Hbt, or the like based on, for example, actuation of user input keys, or the like.


In addition to the foregoing, the display may also include graphical data showing one or more color-coded or other identifying indicia for traces of trend data. Moreover, other graphical presentations may advantageously provide readily identifiable indications of monitored parameters or combinations of monitored parameters of the patient. For example, in an embodiment, the display includes a SpaO2 graph 1172. The SpaO2 graph 1172 plots SpO2 as a function of other blood analytes (1-SpaO2), where SpaO2 comprises HbO2 expressed as a percentage of the four main hemoglobin species, i.e., HbO2, Hb, HbCO, and HbMet. Thus, as shown in FIG. 11C, as the slope of the displayed line or arrow increases, the caregiver can readily note that the majority of hemoglobin carriers are being used to carry oxygen, and not, for example, harmful carbon monoxide. On the other hand, as the slope decreases, the caregiver can readily and advantageously note that the number of hemoglobin species available to carry oxygen is decreasing, regardless of the current value of SpO2. Moreover, the length of the arrow or line also provides an indication of wellness, e.g., the higher the line the more oxygen saturation, the lower the line, the more likely there may be desaturation event, or the like.


Thus, the SpaO2 graph 1172 provides the caregiver with the ability to recognize that even though the measured value of SpO2 may be within acceptable ranges, there are potentially an unacceptable number of hemoglobin carriers unavailable for carrying oxygen, and that other potential problems may exist, such as, for example, harmful carbon monoxide levels, or the like. In an embodiment, various alarm conditions may cause the graph 1172 to change color, flash, or any combination of alarm indications discussed in the forgoing. Moreover, FIG. 11I illustrates yet an additional display of the foregoing parameters.


An embodiment may also include the monitor 1000 advantageously defining regions of wellness/severity of the monitored patient. For example, because the graph 1172 comprises two dimensions, the monitor 1000 may advantageously define regions where the patient's measured physiological parameters are considered acceptable, regions where the patient is considered at risk, regions where the patient is critical, and the like. For example, one region of acceptability may include a high SpO2 and a low 1-SpaO2, another region of risk may include a high SpO2 and a high 1-SpaO2, and another critical region may include a low SpO2 and a high 1-SpaO2. Moreover, an artisan will recognize from the disclosure herein that different parameters may also be combined to provide readily identifiable indications of patient wellness.


In addition to or as an alternative to the two dimensional SpaO2 graph 1172, the monitor 1000 may also include a three dimensional graph, such as, for example, extending the graph 1172 along the variable of time. In this embodiment, the forgoing regions advantageously become three dimensional surfaces of wellness. Moreover, trend data may also be advantageously added to the surface to provide a history of when particular monitored parameters dipped in and out of various surfaces of wellness, risk, criticality, or the like. Such trend data could be color-coded, text identified, or the like. An artisan will also recognize that such surfaces may be dynamic. For example, measurements of HbCO >about 5 may dictate that trend data showing SpO2<about 90% should be considered critical; however, measurements of HbCO <about 5 may dictate only SpO2<about 85% would be critical. Again, an artisan will recognize from the disclosure herein other parameter combinations to create a wide variety of wellness/critical regions or surfaces that provide readily available visual or audio indications of patient well being, trigger specific alarms, or the like.


Moreover, the monitor 1000 may advantageously employ enlargement or reorganization of parameter data based on, for example, the severity of the measurement. For example, the monitor 1000 may display values for HbCO in a small portion of the screen or in the background, and when HbCO begins to approach abnormal levels, the small portion may advantageously grown as severity increases, even in some embodiments to dominate the display. Such visual alarming can be combined with audio alarms such as announcements, alarms, rising frequencies, or the like, and other visual alarms such as flashing, coloration, or the like to assist a caregiver in noticing the increasing severity of a monitored parameter. In an embodiment, a location of the display of an alarming value is changed to be displayed in a larger display area, such as 1102, so as to be readily noticeable and its display values readily ascertainable.


Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, the monitor 100 may advantageously be adapted to monitor or be included in a monitor capable of measuring physiological parameters other than those determined through absorption spectroscopy, such as, for example, blood pressure, ECG, EKG, respiratory rates, volumes, inputs for blood pressure sensors, acoustical sensors, and the like. Moreover, the monitor 100 may be adapted for wireless communication to and from the sensor 106, and/or to and from other monitoring devices, such as, for example, multi-parameter or legacy monitoring devices.


Also, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Accordingly, the present invention is not intended to be limited by the reaction of the preferred embodiments, but is to be defined by reference to the appended claims.


Additionally, all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

Claims
  • 1. A method of determining which of a plurality of physiological measurements to measure based on the signal quality of the signal, the method comprising: using a sensor configured to measure at least two different physiological measurements to obtain a signal from a light sensitive detector, the sensor including at least three different light emitters emitting at least three different wavelengths of light through tissue of a living patient and detecting the light after attenuation of the tissue;determining a signal quality of the signal;driving less than said at least 3 different light emitters to emit light, said driving responsive to the signal quality determination; anddetermining an output value for one of the at least two different measurements responsive to said emitted light.
  • 2. The method of claim 1, wherein if the signal quality is low, only two of the at least three different emitters are activated.
  • 3. The method of claim 1, wherein if the signal quality is low, fewer different physiological measurements are measured.
  • 4. A method of informing a user of a patient monitor about one of a type of sensor communicating with the patient monitor and a type of physiological parameter determinable using the sensor communicating with the patient monitor, the method comprising: receiving information from an information element associated with one of an optical sensor and a communication cable between a patient monitor and an optical sensor;determining a number of wavelengths capable of being emitted by the optical sensor from the information;determining a signal quality of a signal received by the optical sensor; andactivating an indicator of the type of physiological parameters determinable;driving less than the number of wavelengths capable of being emitted by the optical sensor based on the number wavelengths emitted by the optical sensor and the signal quality of the signal.
  • 5. The method of claim 4, wherein the indicator comprises a display of data determined using signals from the optical sensor.
  • 6. The method of claim 4, wherein the indicator comprises a visual indicator.
  • 7. The method of claim 6, wherein the visual indicator comprises a color.
  • 8. The method of claim 6, wherein the visual indicator comprises an LED.
  • 9. The method of claim 8, wherein the LED changes color based on which of the first and second sensors is attached.
  • 10. The method of claim 8, wherein the LED color comprises red when the first sensor is attached and another color when another sensor is attached.
  • 11. The method of claim 4, wherein the indicator comprises an audible indicator.
  • 12. The method of claim 11, wherein the audible indictor comprises one or more tones.
  • 13. The method of claim 11, wherein the audible indictor emits a first tone when the first sensor is attached and a different second tone when the second sensor is attached.
  • 14. A physiological parameter monitor capable of improving performance by activating less light emission sources of an optical sensor, the monitor comprising a processor capable of determining a number of light emission sources available for activation on an attached sensor and capable of activating two of the plurality of light emission sources and capable of activating more than two of the plurality of light emission sources based on a signal quality received from the optical sensor.
  • 15. The monitor of claim 14, wherein the processor activates two of the plurality of light emission sources to measure a first physiological parameter under low signal quality conditions.
  • 16. The monitor of claim 15, wherein the processor activates more than two of the plurality of light emission sources to measure a second physiological parameter under high signal quality conditions.
  • 17. The monitor of claim 15, wherein the processor activates more than two of the plurality of light emission sources to more accurately measure the first physiological parameter.
  • 18. The monitor of claim 14, wherein the processor activates more than two of the plurality of light emission sources to measure a second physiological parameter.
PRIORITY CLAIM TO RELATED PROVISIONAL APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 13/477,975, filed on May 22, 2012, which is a continuation of U.S. patent application Ser. No. 11/367,014, filed on Mar. 1, 2006, which claims priority benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 60/657,596, filed Mar. 1, 2005, entitled “Multiple Wavelength Sensor,” No. 60/657,281, filed Mar. 1, 2005, entitled “Physiological Parameter Confidence Measure,” No. 60/657,268, filed Mar. 1, 2005, entitled “Configurable Physiological Measurement System,” and No. 60/657,759, filed Mar. 1, 2005, entitled “Noninvasive Multi-Parameter Patient Monitor.” The present application incorporates the foregoing disclosures herein by reference.

US Referenced Citations (1007)
Number Name Date Kind
3910701 Henderson et al. Oct 1975 A
3998550 Konishi et al. Dec 1976 A
4014321 March Mar 1977 A
4157708 Imura Jun 1979 A
4167331 Nielsen Sep 1979 A
4266554 Hamaguri May 1981 A
4267844 Yamanishi May 1981 A
4446871 Imura May 1984 A
4531527 Reinhold et al. Jul 1985 A
4586513 Hamaguri May 1986 A
4621643 New et al. Nov 1986 A
4653498 New et al. Mar 1987 A
4655225 Dahne et al. Apr 1987 A
4685464 Goldberger et al. Aug 1987 A
4694833 Hamaguri Sep 1987 A
4700708 New et al. Oct 1987 A
4714341 Hamaguri et al. Dec 1987 A
4770179 New et al. Sep 1988 A
4773422 Isaacson et al. Sep 1988 A
4781195 Martin Nov 1988 A
4800885 Johnson Jan 1989 A
4805623 Jobsis Feb 1989 A
4822997 Fuller et al. Apr 1989 A
4832484 Aoyagi et al. May 1989 A
4846183 Martin Jul 1989 A
4854328 Pollack Aug 1989 A
4863265 Flower et al. Sep 1989 A
4867571 Frick et al. Sep 1989 A
4868476 Respaut Sep 1989 A
4869254 Stone et al. Sep 1989 A
4890306 Noda Dec 1989 A
4907876 Suzuki et al. Mar 1990 A
4911167 Corenman et al. Mar 1990 A
4934372 Corenman et al. Jun 1990 A
4938218 Goodman et al. Jul 1990 A
4942877 Sakai et al. Jul 1990 A
4955379 Hall Sep 1990 A
4960126 Conlon et al. Oct 1990 A
4960128 Gordon et al. Oct 1990 A
4964010 Miyasaka et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
4967571 Sporri Nov 1990 A
4975581 Robinson et al. Dec 1990 A
4975647 Downer et al. Dec 1990 A
4986665 Yamanishi et al. Jan 1991 A
4996975 Nakamura Mar 1991 A
4997769 Lundsgaard Mar 1991 A
5025791 Niwa Jun 1991 A
RE33643 Isaacson et al. Jul 1991 E
5028787 Rosenthal et al. Jul 1991 A
5033472 Sato et al. Jul 1991 A
5041187 Hink et al. Aug 1991 A
5054495 Uemura et al. Oct 1991 A
5058588 Kaestle Oct 1991 A
5069213 Polczynski Dec 1991 A
5077476 Rosenthal Dec 1991 A
5078136 Stone et al. Jan 1992 A
5137023 Mendelson et al. Aug 1992 A
5155697 Bunsen Oct 1992 A
5162725 Hodson et al. Nov 1992 A
5163438 Gordon et al. Nov 1992 A
5189609 Tivig et al. Feb 1993 A
5190040 Aoyagi Mar 1993 A
5209230 Swedlow et al. May 1993 A
5226053 Cho et al. Jul 1993 A
5246002 Prosser Sep 1993 A
5247931 Norwood Sep 1993 A
5259381 Cheung et al. Nov 1993 A
5267562 Ukawa et al. Dec 1993 A
5267563 Swedlow et al. Dec 1993 A
5278627 Aoyagi Jan 1994 A
5297548 Pologe Mar 1994 A
5313940 Fuse et al. May 1994 A
5319355 Russek Jun 1994 A
5331549 Crawford, Jr. Jul 1994 A
5335659 Pologe et al. Aug 1994 A
5337744 Branigan Aug 1994 A
5337745 Benaron Aug 1994 A
5341805 Stavridi et al. Aug 1994 A
5348004 Hollub Sep 1994 A
5351685 Potratz Oct 1994 A
5355129 Baumann Oct 1994 A
5355880 Thomas et al. Oct 1994 A
5355882 Ukawa et al. Oct 1994 A
5361758 Hall et al. Nov 1994 A
5368224 Richardson et al. Nov 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5377676 Vari et al. Jan 1995 A
5383874 Jackson et al. Jan 1995 A
5385143 Aoyagi Jan 1995 A
5387122 Goldberger et al. Feb 1995 A
5392777 Swedlow et al. Feb 1995 A
5400267 Denen et al. Mar 1995 A
5413101 Sugiura May 1995 A
D359546 Savage et al. Jun 1995 S
5421329 Casciani et al. Jun 1995 A
5425362 Siker et al. Jun 1995 A
5425375 Chin et al. Jun 1995 A
5427093 Ogawa et al. Jun 1995 A
5429128 Cadell et al. Jul 1995 A
5431170 Mathews Jul 1995 A
5435309 Thomas et al. Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
5452717 Branigan et al. Sep 1995 A
D363120 Savage et al. Oct 1995 S
5456252 Vari et al. Oct 1995 A
RE35122 Corenman et al. Dec 1995 E
5479934 Imran Jan 1996 A
5482036 Diab et al. Jan 1996 A
5487386 Wakabayashi et al. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5490523 Isaacson et al. Feb 1996 A
5494032 Robinson et al. Feb 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5503148 Pologe et al. Apr 1996 A
5520177 Ogawa May 1996 A
5528519 Ohkura et al. Jun 1996 A
5533507 Potratz Jul 1996 A
5533511 Kaspari et al. Jul 1996 A
5534851 Russek Jul 1996 A
5551423 Sugiura Sep 1996 A
5553615 Carim et al. Sep 1996 A
5555882 Richardson et al. Sep 1996 A
5561275 Savage et al. Oct 1996 A
5562002 Lalin Oct 1996 A
5575284 Athan et al. Nov 1996 A
5577500 Potratz Nov 1996 A
5584299 Sakai et al. Dec 1996 A
5588427 Tien Dec 1996 A
5590649 Caro et al. Jan 1997 A
5590652 Inai Jan 1997 A
5595176 Yamaura Jan 1997 A
5596992 Haaland et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5603323 Pflugrath et al. Feb 1997 A
5603623 Nishikawa et al. Feb 1997 A
5615672 Braig et al. Apr 1997 A
5617857 Chader et al. Apr 1997 A
5630413 Thomas et al. May 1997 A
5632272 Diab et al. May 1997 A
5638816 Kiani/Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645059 Fein et al. Jul 1997 A
5645060 Yorkey Jul 1997 A
5645440 Tobler et al. Jul 1997 A
5651780 Jackson et al. Jul 1997 A
5658248 Klein et al. Aug 1997 A
5660567 Nierlich et al. Aug 1997 A
5662106 Swedlow et al. Sep 1997 A
5676139 Goldberger et al. Oct 1997 A
5676141 Hollub Oct 1997 A
5678544 DeLonzor et al. Oct 1997 A
5685299 Diab et al. Nov 1997 A
5685301 Klomhaus Nov 1997 A
5687719 Sato et al. Nov 1997 A
5687722 Tien et al. Nov 1997 A
5690104 Kanemoto et al. Nov 1997 A
5692503 Kuenstner Dec 1997 A
5697371 Aoyagi Dec 1997 A
5713355 Richardson et al. Feb 1998 A
5719589 Norman et al. Feb 1998 A
5720284 Aoyagi et al. Feb 1998 A
5720293 Quinn et al. Feb 1998 A
D393830 Tobler et al. Apr 1998 S
5742718 Harman et al. Apr 1998 A
5743262 Lepper, Jr. et al. Apr 1998 A
5743263 Baker, Jr. Apr 1998 A
5746206 Mannheimer May 1998 A
5746697 Swedlow et al. May 1998 A
5752914 Delonzor et al. May 1998 A
5755226 Carim et al. May 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5772587 Gratton et al. Jun 1998 A
5779630 Fein et al. Jul 1998 A
5782237 Casciani et al. Jul 1998 A
5782756 Mannheimer Jul 1998 A
5782757 Diab et al. Jul 1998 A
5785659 Caro et al. Jul 1998 A
5790729 Pologe et al. Aug 1998 A
5791347 Flaherty et al. Aug 1998 A
5792052 Isaacson et al. Aug 1998 A
5793485 Gourley Aug 1998 A
5800348 Kaestle et al. Sep 1998 A
5800349 Isaacson et al. Sep 1998 A
5803910 Potratz Sep 1998 A
5807246 Sakaguchi et al. Sep 1998 A
5807247 Merchant et al. Sep 1998 A
5810723 Aldrich Sep 1998 A
5810724 Gronvall Sep 1998 A
5810734 Caro et al. Sep 1998 A
5817010 Hibl Oct 1998 A
5818985 Merchant et al. Oct 1998 A
5823950 Diab et al. Oct 1998 A
5823952 Levinson et al. Oct 1998 A
5827182 Raley Oct 1998 A
5830121 Enomoto et al. Nov 1998 A
5830131 Caro et al. Nov 1998 A
5830137 Scharf Nov 1998 A
5833618 Caro et al. Nov 1998 A
5839439 Nierlich et al. Nov 1998 A
RE36000 Swedlow et al. Dec 1998 E
5842979 Jarman Dec 1998 A
5850443 Van Oorschot et al. Dec 1998 A
5851178 Aronow Dec 1998 A
5851179 Ritson et al. Dec 1998 A
5853364 Baker, Jr. et al. Dec 1998 A
5857462 Thomas et al. Jan 1999 A
5860099 Milios et al. Jan 1999 A
5860919 Kiani/Azarbayjany et al. Jan 1999 A
5865736 Baker, Jr. et al. Feb 1999 A
5876348 Sugo Mar 1999 A
5885213 Richardson et al. Mar 1999 A
5890929 Mills et al. Apr 1999 A
5891022 Pologe Apr 1999 A
5891024 Jarman et al. Apr 1999 A
5900632 Sterling et al. May 1999 A
5904654 Wohltmann et al. May 1999 A
5910108 Solenberger Jun 1999 A
5916154 Hobbs et al. Jun 1999 A
5919133 Taylor Jul 1999 A
5919134 Diab Jul 1999 A
5921921 Potratz et al. Jul 1999 A
5934277 Mortz Aug 1999 A
5934925 Tobler et al. Aug 1999 A
5939609 Knapp et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5954644 Dettling Sep 1999 A
5978691 Mills Nov 1999 A
5983122 Jarman et al. Nov 1999 A
5987343 Kinast Nov 1999 A
5991355 Dahlke Nov 1999 A
5995855 Kiani et al. Nov 1999 A
5995856 Mannheimer et al. Nov 1999 A
5995859 Takahashi Nov 1999 A
5997343 Mills et al. Dec 1999 A
5999841 Aoyagi et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6006119 Soller et al. Dec 1999 A
6011986 Diab et al. Jan 2000 A
6014576 Raley Jan 2000 A
6018673 Chin et al. Jan 2000 A
6018674 Aronow Jan 2000 A
6023541 Merchant et al. Feb 2000 A
6027452 Flaherty et al. Feb 2000 A
6036642 Diab et al. Mar 2000 A
6045509 Caro et al. Apr 2000 A
6064898 Aldrich May 2000 A
6067462 Diab et al. May 2000 A
6068594 Schloemer et al. May 2000 A
6073037 Alam et al. Jun 2000 A
6081735 Diab et al. Jun 2000 A
6083172 Baker, Jr. et al. Jul 2000 A
6088607 Diab et al. Jul 2000 A
6094592 Yorkey et al. Jul 2000 A
6104938 Huiku Aug 2000 A
6110522 Lepper, Jr. et al. Aug 2000 A
6112107 Hannula Aug 2000 A
6122042 Wunderman et al. Sep 2000 A
6124597 Shehada Sep 2000 A
6128521 Marro et al. Oct 2000 A
6129675 Jay Oct 2000 A
6132363 Freed et al. Oct 2000 A
6144868 Parker Nov 2000 A
6149588 Noda et al. Nov 2000 A
6151516 Kiani/Azarbayjany et al. Nov 2000 A
6151518 Hayashi Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6154667 Miura et al. Nov 2000 A
6157041 Thomas et al. Dec 2000 A
6157850 Diab et al. Dec 2000 A
6163715 Larsen et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6165173 Kamdar et al. Dec 2000 A
6174283 Nevo et al. Jan 2001 B1
6175752 Say et al. Jan 2001 B1
6184521 Coffin, IV et al. Feb 2001 B1
6192261 Gratton et al. Feb 2001 B1
6206830 Diab et al. Mar 2001 B1
6226539 Potratz May 2001 B1
6229856 Diab et al. May 2001 B1
6230035 Aoyagi et al. May 2001 B1
6232609 Snyder et al. May 2001 B1
6236872 Diab et al. May 2001 B1
6237604 Burnside et al. May 2001 B1
6241683 Macklem et al. Jun 2001 B1
6253097 Aronow et al. Jun 2001 B1
6256523 Diab et al. Jul 2001 B1
6262698 Blum Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6266551 Osadchy et al. Jul 2001 B1
6272363 Casciani et al. Aug 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6285895 Ristolainen et al. Sep 2001 B1
6285896 Tobler et al. Sep 2001 B1
6295330 Skog et al. Sep 2001 B1
6298252 Kovach et al. Oct 2001 B1
6298255 Cordero et al. Oct 2001 B1
6301493 Marro et al. Oct 2001 B1
6304675 Osbourn et al. Oct 2001 B1
6304767 Soller et al. Oct 2001 B1
6317627 Ennen et al. Nov 2001 B1
6321100 Parker Nov 2001 B1
6325761 Jay Dec 2001 B1
6330468 Scharf Dec 2001 B1
6334065 Al/Ali et al. Dec 2001 B1
6336900 Alleckson et al. Jan 2002 B1
6339715 Bahr et al. Jan 2002 B1
6341257 Haaland Jan 2002 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6351658 Middleman et al. Feb 2002 B1
6356774 Bernstein et al. Mar 2002 B1
6360113 Dettling Mar 2002 B1
6360114 Diab et al. Mar 2002 B1
6363269 Hanna et al. Mar 2002 B1
6368283 Xu et al. Apr 2002 B1
6371921 Caro et al. Apr 2002 B1
6374129 Chin et al. Apr 2002 B1
6377828 Chaiken et al. Apr 2002 B1
6377829 Al/Ali Apr 2002 B1
6388240 Schulz et al. May 2002 B2
6393310 Kuenstner May 2002 B1
6397091 Diab et al. May 2002 B2
6397092 Norris et al. May 2002 B1
6397093 Aldrich May 2002 B1
6408198 Hanna et al. Jun 2002 B1
6411833 Baker, Jr. et al. Jun 2002 B1
6415166 Van Hoy et al. Jul 2002 B1
6415233 Haaland Jul 2002 B1
6415236 Kobayashi et al. Jul 2002 B2
6430437 Marro Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6434408 Heckel Aug 2002 B1
6441388 Thomas et al. Aug 2002 B1
6453184 Hyogo et al. Sep 2002 B1
6455340 Chua et al. Sep 2002 B1
6463310 Swedlow et al. Oct 2002 B1
6463311 Diab Oct 2002 B1
6466824 Struble Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6480729 Stone Nov 2002 B2
6490466 Fein et al. Dec 2002 B1
6490684 Fenstemaker et al. Dec 2002 B1
6497659 Rafert Dec 2002 B1
6501974 Huiku Dec 2002 B2
6501975 Diab et al. Dec 2002 B2
6504943 Sweatt et al. Jan 2003 B1
6505059 Kollias et al. Jan 2003 B1
6505060 Norris Jan 2003 B1
6505061 Larson Jan 2003 B2
6505133 Hanna Jan 2003 B1
6510329 Heckel Jan 2003 B2
6515273 Al/Ali Feb 2003 B2
6519486 Edgar, Jr. et al. Feb 2003 B1
6519487 Parker Feb 2003 B1
6522398 Cadell et al. Feb 2003 B2
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6526301 Larsen et al. Feb 2003 B2
6528809 Thomas et al. Mar 2003 B1
6537225 Mills Mar 2003 B1
6541756 Schulz et al. Apr 2003 B2
6542763 Yamashita et al. Apr 2003 B1
6542764 Al/Ali et al. Apr 2003 B1
6545652 Tsuji Apr 2003 B1
6546267 Sugiura Apr 2003 B1
6553241 Mannheimer et al. Apr 2003 B2
6564077 Mortara May 2003 B2
6571113 Fein et al. May 2003 B1
6580086 Schulz et al. Jun 2003 B1
6582964 Samsoondar et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6584413 Keenan et al. Jun 2003 B1
6591123 Fein et al. Jul 2003 B2
6594511 Stone et al. Jul 2003 B2
6595316 Cybulski et al. Jul 2003 B2
6597932 Tian et al. Jul 2003 B2
6597933 Kiani et al. Jul 2003 B2
6600940 Fein et al. Jul 2003 B1
6606509 Schmitt Aug 2003 B2
6606510 Swedlow et al. Aug 2003 B2
6606511 Ali et al. Aug 2003 B1
6611698 Yamashita et al. Aug 2003 B1
6614521 Samsoondar et al. Sep 2003 B2
6615064 Aldrich Sep 2003 B1
6615151 Scecina et al. Sep 2003 B1
6618602 Levin Sep 2003 B2
6622095 Kobayashi et al. Sep 2003 B2
6628975 Fein et al. Sep 2003 B1
6631281 Kastle Oct 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6639668 Trepagnier Oct 2003 B1
6640116 Diab Oct 2003 B2
6643530 Diab et al. Nov 2003 B2
6645142 Braig et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654623 Kastle Nov 2003 B1
6654624 Diab et al. Nov 2003 B2
6657717 Cadell et al. Dec 2003 B2
6658276 Kiani et al. Dec 2003 B2
6658277 Wasserman Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6662033 Casciani et al. Dec 2003 B2
6665551 Suzuki Dec 2003 B1
6668183 Hicks et al. Dec 2003 B2
6671526 Aoyagi et al. Dec 2003 B1
6671531 Al/Ali et al. Dec 2003 B2
6675031 Porges et al. Jan 2004 B1
6675106 Keenan et al. Jan 2004 B1
6676600 Conero et al. Jan 2004 B1
6678543 Diab et al. Jan 2004 B2
6681126 Solenberger Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6687620 Haaland et al. Feb 2004 B1
6690466 Miller et al. Feb 2004 B2
6694157 Stone et al. Feb 2004 B1
6697655 Sueppel et al. Feb 2004 B2
6697656 Al/Ali Feb 2004 B1
6697657 Shehada et al. Feb 2004 B1
6697658 Al/Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6701170 Stetson Mar 2004 B2
6708049 Berson et al. Mar 2004 B1
6711503 Haaland Mar 2004 B2
6714803 Mortz Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
6714805 Jeon et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6719705 Mills Apr 2004 B2
6720734 Norris Apr 2004 B2
6721582 Trepagnier et al. Apr 2004 B2
6721584 Baker, Jr. et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725074 Kastle Apr 2004 B1
6725075 Al/Ali Apr 2004 B2
6726634 Freeman Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6735459 Parker May 2004 B2
6741875 Pawluczyk et al. May 2004 B1
6741876 Scecina et al. May 2004 B1
6743172 Blike Jun 2004 B1
6745060 Diab et al. Jun 2004 B2
6745061 Hicks et al. Jun 2004 B1
6748253 Norris et al. Jun 2004 B2
6748254 O'Neil et al. Jun 2004 B2
6754515 Pologe Jun 2004 B1
6754516 Mannheimer Jun 2004 B2
6760607 Al/Ali Jul 2004 B2
6760609 Jacques Jul 2004 B2
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6773397 Kelly Aug 2004 B2
6778923 Norris et al. Aug 2004 B2
6780158 Yarita Aug 2004 B2
6788849 Pawluczyk Sep 2004 B1
6792300 Diab et al. Sep 2004 B1
6800373 Gorczyca Oct 2004 B2
6801797 Mannheimer et al. Oct 2004 B2
6801799 Mendelson Oct 2004 B2
6810277 Edgar, Jr. et al. Oct 2004 B2
6813511 Diab et al. Nov 2004 B2
6816741 Diab Nov 2004 B2
6819950 Mills Nov 2004 B2
6822564 Al/Ali Nov 2004 B2
6825619 Norris Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6829496 Nagai et al. Dec 2004 B2
6829501 Nielsen et al. Dec 2004 B2
6830711 Mills et al. Dec 2004 B2
6836679 Baker, Jr. et al. Dec 2004 B2
6839579 Chin Jan 2005 B1
6839580 Zonios et al. Jan 2005 B2
6839582 Heckel Jan 2005 B2
6842702 Haaland et al. Jan 2005 B2
6845256 Chin et al. Jan 2005 B2
6847835 Yamanishi Jan 2005 B1
6850787 Weber et al. Feb 2005 B2
6850788 Al/Ali Feb 2005 B2
6852083 Caro et al. Feb 2005 B2
6861639 Al/Ali Mar 2005 B2
6861641 Adams Mar 2005 B1
6869402 Arnold Mar 2005 B2
6882874 Huiku Apr 2005 B2
6898452 Al/Ali et al. May 2005 B2
6912049 Pawluczyk et al. Jun 2005 B2
6917422 Samsoondar et al. Jul 2005 B2
6919566 Cadell Jul 2005 B1
6920345 Al/Ali et al. Jul 2005 B2
6921367 Mills Jul 2005 B2
6922645 Haaland et al. Jul 2005 B2
6928311 Pawluczyk et al. Aug 2005 B1
6931268 Kiani/Azarbayjany et al. Aug 2005 B1
6931269 Terry Aug 2005 B2
6934570 Kiani et al. Aug 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6943348 Coffin, IV Sep 2005 B1
6944487 Maynard et al. Sep 2005 B2
6950687 Al/Ali Sep 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6975891 Pawluczyk Dec 2005 B2
6979812 Al/Ali Dec 2005 B2
6985764 Mason et al. Jan 2006 B2
6987994 Mortz Jan 2006 B1
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
6999904 Weber et al. Feb 2006 B2
7001337 Dekker Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7006856 Baker, Jr. et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7024233 Ali et al. Apr 2006 B2
7027849 Al/Ali Apr 2006 B2
7030749 Al/Ali Apr 2006 B2
7039449 Al/Ali May 2006 B2
7041060 Flaherty et al. May 2006 B2
7044918 Diab May 2006 B2
7067893 Mills et al. Jun 2006 B2
7096052 Mason et al. Aug 2006 B2
7096054 Abdul/Hafiz et al. Aug 2006 B2
7132641 Schulz et al. Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7149561 Diab Dec 2006 B2
7186966 Al/Ali Mar 2007 B2
7190261 Al/Ali Mar 2007 B2
7215984 Diab May 2007 B2
7215986 Diab May 2007 B2
7221971 Diab May 2007 B2
7225006 Al/Ali et al. May 2007 B2
7225007 Al/Ali May 2007 B2
RE39672 Shehada et al. Jun 2007 E
7239905 Kiani/Azarbayjany et al. Jul 2007 B2
7245953 Parker Jul 2007 B1
7254429 Schurman et al. Aug 2007 B2
7254431 Al/Ali Aug 2007 B2
7254433 Diab et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7272425 Al/Ali Sep 2007 B2
7274955 Kiani et al. Sep 2007 B2
D554263 Al/Ali Oct 2007 S
7280858 Al/Ali et al. Oct 2007 B2
7289835 Mansfield et al. Oct 2007 B2
7292883 De Felice et al. Nov 2007 B2
7295866 Al/Ali Nov 2007 B2
7299080 Acosta et al. Nov 2007 B2
7328053 Diab et al. Feb 2008 B1
7332784 Mills et al. Feb 2008 B2
7340287 Mason et al. Mar 2008 B2
7341559 Schulz et al. Mar 2008 B2
7343186 Lamego et al. Mar 2008 B2
D566282 Al/Ali et al. Apr 2008 S
7355512 Al/Ali Apr 2008 B1
7356365 Schurman Apr 2008 B2
7371981 Abdul/Hafiz May 2008 B2
7373193 Al/Ali et al. May 2008 B2
7373194 Weber et al. May 2008 B2
7376453 Diab et al. May 2008 B1
7377794 Al/Ali et al. May 2008 B2
7377899 Weber et al. May 2008 B2
7383070 Diab et al. Jun 2008 B2
7415297 Al/Ali et al. Aug 2008 B2
7428432 Ali et al. Sep 2008 B2
7438683 Al/Ali et al. Oct 2008 B2
7440787 Diab Oct 2008 B2
7454240 Diab et al. Nov 2008 B2
7467002 Weber et al. Dec 2008 B2
7469157 Diab et al. Dec 2008 B2
7471969 Diab et al. Dec 2008 B2
7471971 Diab et al. Dec 2008 B2
7483729 Al/Ali et al. Jan 2009 B2
7483730 Diab et al. Jan 2009 B2
7489958 Diab et al. Feb 2009 B2
7496391 Diab et al. Feb 2009 B2
7496393 Diab et al. Feb 2009 B2
D587657 Al/Ali et al. Mar 2009 S
7499741 Diab et al. Mar 2009 B2
7499835 Weber et al. Mar 2009 B2
7500950 Al/Ali et al. Mar 2009 B2
7509154 Diab et al. Mar 2009 B2
7509494 Al/Ali Mar 2009 B2
7510849 Schurman et al. Mar 2009 B2
7526328 Diab et al. Apr 2009 B2
7530942 Diab May 2009 B1
7530949 Al Ali et al. May 2009 B2
7530955 Diab et al. May 2009 B2
7563110 Al/Ali et al. Jul 2009 B2
7596398 Al/Ali et al. Sep 2009 B2
7606861 Killcommons et al. Oct 2009 B2
7618375 Flaherty Nov 2009 B2
D606659 Kiani et al. Dec 2009 S
7647083 Al/Ali et al. Jan 2010 B2
D609193 Al/Ali et al. Feb 2010 S
D614305 Al/Ali et al. Apr 2010 S
RE41317 Parker May 2010 E
7729733 Al/Ali et al. Jun 2010 B2
7734320 Al/Ali Jun 2010 B2
7761127 Al/Ali et al. Jul 2010 B2
7761128 Al/Ali et al. Jul 2010 B2
7764982 Dalke et al. Jul 2010 B2
D621516 Kiani et al. Aug 2010 S
7791155 Diab Sep 2010 B2
7801581 Diab Sep 2010 B2
7822452 Schurman et al. Oct 2010 B2
RE41912 Parker Nov 2010 E
7844313 Kiani et al. Nov 2010 B2
7844314 Al/Ali Nov 2010 B2
7844315 Al/Ali Nov 2010 B2
7865222 Weber et al. Jan 2011 B2
7873497 Weber et al. Jan 2011 B2
7880606 Al/Ali Feb 2011 B2
7880626 Al/Ali et al. Feb 2011 B2
7891355 Al/Ali et al. Feb 2011 B2
7894868 Al/Ali et al. Feb 2011 B2
7899507 Al/Ali et al. Mar 2011 B2
7899518 Trepagnier et al. Mar 2011 B2
7904132 Weber et al. Mar 2011 B2
7909772 Popov et al. Mar 2011 B2
7910875 Al/Ali Mar 2011 B2
7919713 Al/Ali et al. Apr 2011 B2
7937128 Al/Ali May 2011 B2
7937129 Mason et al. May 2011 B2
7937130 Diab et al. May 2011 B2
7941199 Kiani May 2011 B2
7951086 Flaherty et al. May 2011 B2
7957780 Lamego et al. Jun 2011 B2
7962188 Kiani et al. Jun 2011 B2
7962190 Diab et al. Jun 2011 B1
7976472 Kiani Jul 2011 B2
7988637 Diab Aug 2011 B2
7990382 Kiani Aug 2011 B2
7991446 Al/Ali et al. Aug 2011 B2
8000761 Al/Ali Aug 2011 B2
8008088 Bellott et al. Aug 2011 B2
RE42753 Kiani/Azarbayjany et al. Sep 2011 E
8019400 Diab et al. Sep 2011 B2
8028701 Al/Ali et al. Oct 2011 B2
8029765 Bellott et al. Oct 2011 B2
8036728 Diab et al. Oct 2011 B2
8046040 Ali et al. Oct 2011 B2
8046041 Diab et al. Oct 2011 B2
8046042 Diab et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8050728 Al/Ali et al. Nov 2011 B2
RE43169 Parker Feb 2012 E
8118620 Al/Ali et al. Feb 2012 B2
8126528 Diab et al. Feb 2012 B2
8128572 Diab et al. Mar 2012 B2
8130105 Al/Ali et al. Mar 2012 B2
8145287 Diab et al. Mar 2012 B2
8150487 Diab et al. Apr 2012 B2
8175672 Parker May 2012 B2
8180420 Diab et al. May 2012 B2
8182443 Kiani May 2012 B1
8185180 Diab et al. May 2012 B2
8190223 Al/Ali et al. May 2012 B2
8190227 Diab et al. May 2012 B2
8203438 Kiani et al. Jun 2012 B2
8224411 Al/Ali et al. Jul 2012 B2
8228181 Al/Ali Jul 2012 B2
8229533 Diab et al. Jul 2012 B2
8233955 Al/Ali et al. Jul 2012 B2
8244325 Al/Ali et al. Aug 2012 B2
8255026 Al/Ali Aug 2012 B1
8255027 Al/Ali et al. Aug 2012 B2
8255028 Al/Ali et al. Aug 2012 B2
8260577 Weber et al. Sep 2012 B2
8265723 McHale et al. Sep 2012 B1
8274360 Sampath et al. Sep 2012 B2
8301217 Al/Ali et al. Oct 2012 B2
8310336 Muhsin et al. Nov 2012 B2
8315683 Al/Ali et al. Nov 2012 B2
RE43860 Parker Dec 2012 E
8337403 Al/Ali et al. Dec 2012 B2
8346330 Lamego Jan 2013 B2
8353842 Al/Ali et al. Jan 2013 B2
8355766 MacNeish, III et al. Jan 2013 B2
8359080 Diab et al. Jan 2013 B2
8364223 Al/Ali et al. Jan 2013 B2
8364226 Diab et al. Jan 2013 B2
8374665 Lamego Feb 2013 B2
8385995 Al/Ali et al. Feb 2013 B2
8385996 Smith et al. Feb 2013 B2
8388353 Kiani et al. Mar 2013 B2
8399822 Al/Ali Mar 2013 B2
8401602 Kiani Mar 2013 B2
8405608 Al/Ali et al. Mar 2013 B2
8414499 Al/Ali et al. Apr 2013 B2
8418524 Al/Ali Apr 2013 B2
8423106 Lamego et al. Apr 2013 B2
8428967 Olsen et al. Apr 2013 B2
8430817 Al/Ali et al. Apr 2013 B1
8437825 Dalvi et al. May 2013 B2
8455290 Siskavich Jun 2013 B2
8457703 Al/Ali Jun 2013 B2
8457707 Kiani Jun 2013 B2
8463349 Diab et al. Jun 2013 B2
8466286 Bellott et al. Jun 2013 B2
8471713 Poeze et al. Jun 2013 B2
8473020 Kiani et al. Jun 2013 B2
8483787 Al/Ali et al. Jul 2013 B2
8489364 Weber et al. Jul 2013 B2
8498684 Weber et al. Jul 2013 B2
8509867 Workman et al. Aug 2013 B2
8515509 Bruinsma et al. Aug 2013 B2
8523781 Al/Ali Sep 2013 B2
8529301 Al/Ali et al. Sep 2013 B2
8532727 Ali et al. Sep 2013 B2
8532728 Diab et al. Sep 2013 B2
D692145 Al-Ali et al. Oct 2013 S
8547209 Kiani et al. Oct 2013 B2
8548548 Al/Ali Oct 2013 B2
8548550 Al/Ali et al. Oct 2013 B2
8560032 Al/Ali et al. Oct 2013 B2
8560034 Diab et al. Oct 2013 B1
8570167 Al-Ali Oct 2013 B2
8570503 Vo et al. Oct 2013 B2
8571617 Reichgott et al. Oct 2013 B2
8571618 Lamego et al. Oct 2013 B1
8571619 Al-Ali et al. Oct 2013 B2
8577431 Lamego et al. Nov 2013 B2
8581732 Al-Ali et al. Nov 2013 B2
8584345 Al-Ali et al. Nov 2013 B2
8588880 Abdul-Hafiz et al. Nov 2013 B2
8600467 Al-Ali et al. Dec 2013 B2
8606342 Diab Dec 2013 B2
8626255 Al-Ali et al. Jan 2014 B2
8630691 Lamego et al. Jan 2014 B2
8634889 Al-Ali et al. Jan 2014 B2
8641631 Sierra et al. Feb 2014 B2
8652060 Al-Ali Feb 2014 B2
8663107 Kiani Mar 2014 B2
8666468 Al-Ali Mar 2014 B1
8667967 Al-Ali et al. Mar 2014 B2
8670811 O'Reilly Mar 2014 B2
8670814 Diab et al. Mar 2014 B2
8676286 Weber et al. Mar 2014 B2
8682407 Al-Ali Mar 2014 B2
RE44823 Parker Apr 2014 E
RE44875 Kiani et al. Apr 2014 E
8690799 Telfort et al. Apr 2014 B2
8700112 Kiani Apr 2014 B2
8702627 Telfort et al. Apr 2014 B2
8706179 Parker Apr 2014 B2
8712494 MacNeish, III et al. Apr 2014 B1
8715206 Telfort et al. May 2014 B2
8718735 Lamego et al. May 2014 B2
8718737 Diab et al. May 2014 B2
8718738 Blank et al. May 2014 B2
8720249 Al-Ali May 2014 B2
8721541 Al-Ali et al. May 2014 B2
8721542 Al-Ali et al. May 2014 B2
8723677 Kiani May 2014 B1
8740792 Kiani et al. Jun 2014 B1
8754776 Poeze et al. Jun 2014 B2
8755535 Telfort et al. Jun 2014 B2
8755856 Diab et al. Jun 2014 B2
8755872 Marinow Jun 2014 B1
8761850 Lamego Jun 2014 B2
8764671 Kiani Jul 2014 B2
8768423 Shakespeare et al. Jul 2014 B2
8771204 Telfort et al. Jul 2014 B2
8777634 Kiani et al. Jul 2014 B2
8781543 Diab et al. Jul 2014 B2
8781544 Al-Ali et al. Jul 2014 B2
8781549 Al-Ali et al. Jul 2014 B2
8788003 Schurman et al. Jul 2014 B2
8790268 Al-Ali Jul 2014 B2
8801613 Al-Ali et al. Aug 2014 B2
8821397 Al-Ali et al. Sep 2014 B2
8821415 Al-Ali et al. Sep 2014 B2
8830449 Lamego et al. Sep 2014 B1
8831700 Schurman et al. Sep 2014 B2
8840549 Al-Ali et al. Sep 2014 B2
8847740 Kiani et al. Sep 2014 B2
8849365 Smith et al. Sep 2014 B2
8852094 Al-Ali et al. Oct 2014 B2
8852994 Wojtczuk et al. Oct 2014 B2
8868147 Stippick et al. Oct 2014 B2
8868150 Al-Ali et al. Oct 2014 B2
8870792 Al-Ali et al. Oct 2014 B2
8886271 Kiani et al. Nov 2014 B2
8888539 Al-Ali et al. Nov 2014 B2
8888708 Diab et al. Nov 2014 B2
8892180 Weber et al. Nov 2014 B2
8897847 Al-Ali Nov 2014 B2
8909310 Lamego et al. Dec 2014 B2
20010044700 Kobayashi et al. Nov 2001 A1
20010045532 Schulz et al. Nov 2001 A1
20020021269 Rast Feb 2002 A1
20020026107 Kiani et al. Feb 2002 A1
20020035318 Mannheimer et al. Mar 2002 A1
20020038078 Ito Mar 2002 A1
20020038081 Fein et al. Mar 2002 A1
20020059047 Haaland May 2002 A1
20020068858 Braig et al. Jun 2002 A1
20020082488 Al-Ali et al. Jun 2002 A1
20020095077 Swedlow et al. Jul 2002 A1
20020095078 Mannheimer et al. Jul 2002 A1
20020111748 Kobayashi et al. Aug 2002 A1
20020115919 Al-Ali Aug 2002 A1
20020154665 Funabashi et al. Oct 2002 A1
20020156353 Larson Oct 2002 A1
20020159002 Chang Oct 2002 A1
20020161291 Kianl et al. Oct 2002 A1
20020165440 Mason et al. Nov 2002 A1
20020183819 Struble Dec 2002 A1
20030045784 Palatnik et al. Mar 2003 A1
20030045785 Diab et al. Mar 2003 A1
20030049232 Page et al. Mar 2003 A1
20030109775 O'Neil et al. Jun 2003 A1
20030116769 Song et al. Jun 2003 A1
20030117296 Seely Jun 2003 A1
20030120160 Yarita Jun 2003 A1
20030120164 Nielsen et al. Jun 2003 A1
20030135099 Al-Ali Jul 2003 A1
20030139657 Solenberger Jul 2003 A1
20030160257 Bader et al. Aug 2003 A1
20030195402 Fein et al. Oct 2003 A1
20040006261 Swedlow et al. Jan 2004 A1
20040033618 Haass et al. Feb 2004 A1
20040034898 Bruegl Feb 2004 A1
20040059209 Al-Ali et al. Mar 2004 A1
20040064259 Haaland et al. Apr 2004 A1
20040081621 Arndt et al. Apr 2004 A1
20040092805 Yarita May 2004 A1
20040133087 Ali et al. Jul 2004 A1
20040138538 Stetson Jul 2004 A1
20040138540 Baker, Jr. et al. Jul 2004 A1
20040147822 Al-Ali et al. Jul 2004 A1
20040147823 Kiani et al. Jul 2004 A1
20040158132 Zaleski Aug 2004 A1
20040158134 Diab et al. Aug 2004 A1
20040158135 Baker, Jr. et al. Aug 2004 A1
20040162472 Berson et al. Aug 2004 A1
20040167382 Gardner et al. Aug 2004 A1
20040176670 Takamura et al. Sep 2004 A1
20040181134 Baker, Jr. et al. Sep 2004 A1
20040199063 O'Neil et al. Oct 2004 A1
20040204639 Casciani et al. Oct 2004 A1
20040204868 Maynard et al. Oct 2004 A1
20040229391 Ohya et al. Nov 2004 A1
20040262046 Simond et al. Dec 2004 A1
20040267103 Li et al. Dec 2004 A1
20040267140 Ito et al. Dec 2004 A1
20050011488 Doucet Jan 2005 A1
20050043902 Haaland et al. Feb 2005 A1
20050049469 Aoyagi et al. Mar 2005 A1
20050054908 Blank et al. Mar 2005 A1
20050070773 Chin et al. Mar 2005 A1
20050070775 Chin et al. Mar 2005 A1
20050075546 Samsoondar et al. Apr 2005 A1
20050085704 Schulz et al. Apr 2005 A1
20050085735 Baker, Jr. et al. Apr 2005 A1
20050124871 Baker, Jr. et al. Jun 2005 A1
20050143634 Baker, Jr. et al. Jun 2005 A1
20050143943 Brown Jun 2005 A1
20050148834 Hull et al. Jul 2005 A1
20050184895 Petersen et al. Aug 2005 A1
20050187447 Chew et al. Aug 2005 A1
20050187448 Petersen et al. Aug 2005 A1
20050187449 Chew et al. Aug 2005 A1
20050187450 Chew et al. Aug 2005 A1
20050187452 Petersen et al. Aug 2005 A1
20050187453 Petersen et al. Aug 2005 A1
20050197549 Baker, Jr. Sep 2005 A1
20050197579 Baker, Jr. Sep 2005 A1
20050197793 Baker, Jr. Sep 2005 A1
20050203357 Debreczeny et al. Sep 2005 A1
20050209515 Hockersmith et al. Sep 2005 A1
20050228253 Debreczeny Oct 2005 A1
20050250997 Takeda et al. Nov 2005 A1
20060030764 Porges et al. Feb 2006 A1
20060210120 Rowe et al. Sep 2006 A1
20060211922 Al-Ali et al. Sep 2006 A1
20060211923 Al-Ali et al. Sep 2006 A1
20060211924 Smith et al. Sep 2006 A1
20060211925 Lamego et al. Sep 2006 A1
20060211932 Al-Ali et al. Sep 2006 A1
20060226992 Al-Ali et al. Oct 2006 A1
20060229509 Al-Ali et al. Oct 2006 A1
20060238358 Al-Ali et al. Oct 2006 A1
20060241358 Al-Ali et al. Oct 2006 A1
20060241363 Al-Ali et al. Oct 2006 A1
20090247984 Lamego et al. Oct 2009 A1
20090275844 Al-Ali Nov 2009 A1
20090299157 Telfort et al. Dec 2009 A1
20100004518 Vo et al. Jan 2010 A1
20100030040 Poeze et al. Feb 2010 A1
20100069725 Al-Ali Mar 2010 A1
20100261979 Kiani Oct 2010 A1
20100317936 Al-Ali et al. Dec 2010 A1
20110001605 Kiani et al. Jan 2011 A1
20110009719 Al-Ali et al. Jan 2011 A1
20110082711 Poeze et al. Apr 2011 A1
20110105854 Kiani et al. May 2011 A1
20110172967 Al-Ali et al. Jul 2011 A1
20110208015 Welch et al. Aug 2011 A1
20110209915 Telfort et al. Sep 2011 A1
20110213212 Al-Ali Sep 2011 A1
20110230733 Al-Ali Sep 2011 A1
20110237911 Lamego et al. Sep 2011 A1
20110237914 Lamego Sep 2011 A1
20120059267 Lamego et al. Mar 2012 A1
20120116175 Al-Ali et al. May 2012 A1
20120179006 Jansen et al. Jul 2012 A1
20120209082 Al-Ali Aug 2012 A1
20120209084 Olsen et al. Aug 2012 A1
20120227739 Kiani Sep 2012 A1
20120265039 Kiani Oct 2012 A1
20120283524 Kiani et al. Nov 2012 A1
20120286955 Welch et al. Nov 2012 A1
20120296178 Lamego et al. Nov 2012 A1
20120319816 Al-Ali Dec 2012 A1
20120330112 Lamego et al. Dec 2012 A1
20130023775 Lamego et al. Jan 2013 A1
20130041591 Lamego Feb 2013 A1
20130045685 Kiani Feb 2013 A1
20130046204 Lamego et al. Feb 2013 A1
20130060108 Schurman et al. Mar 2013 A1
20130060147 Welch et al. Mar 2013 A1
20130079610 Al-Ali Mar 2013 A1
20130096405 Garfio Apr 2013 A1
20130096936 Sampath et al. Apr 2013 A1
20130109935 Al-Ali et al. May 2013 A1
20130162433 Muhsin et al. Jun 2013 A1
20130178749 Lamego Jul 2013 A1
20130190581 Al-Ali et al. Jul 2013 A1
20130197328 Diab et al. Aug 2013 A1
20130211214 Olsen Aug 2013 A1
20130243021 Siskavich Sep 2013 A1
20130253334 Al-Ali et al. Sep 2013 A1
20130274571 Diab et al. Oct 2013 A1
20130296672 O'Neil et al. Nov 2013 A1
20130317327 Al-Ali et al. Nov 2013 A1
20130317370 Dalvi et al. Nov 2013 A1
20130324808 Al-Ali et al. Dec 2013 A1
20130324817 Diab Dec 2013 A1
20130331670 Kiani Dec 2013 A1
20130338461 Lamego et al. Dec 2013 A1
20140012100 Al-Ali et al. Jan 2014 A1
20140025306 Weber et al. Jan 2014 A1
20140034353 Al-Ali et al. Feb 2014 A1
20140051952 Reichgott et al. Feb 2014 A1
20140051953 Lamego et al. Feb 2014 A1
20140051954 Al-Ali et al. Feb 2014 A1
20140058230 Abdul-Hafiz et al. Feb 2014 A1
20140066783 Kiani et al. Mar 2014 A1
20140077956 Sampath et al. Mar 2014 A1
20140081097 Al-Ali et al. Mar 2014 A1
20140081100 Muhsin et al. Mar 2014 A1
20140081175 Telfort Mar 2014 A1
20140094667 Schurman et al. Apr 2014 A1
20140100434 Diab et al. Apr 2014 A1
20140114199 Lamego et al. Apr 2014 A1
20140120564 Workman et al. May 2014 A1
20140121482 Merritt et al. May 2014 A1
20140121483 Kiani May 2014 A1
20140125495 Al-Ali May 2014 A1
20140127137 Bellott et al. May 2014 A1
20140128696 Al-Ali May 2014 A1
20140128699 Al-Ali et al. May 2014 A1
20140129702 Lamego et al. May 2014 A1
20140135588 Al-Ali et al. May 2014 A1
20140142399 Al-Ali et al. May 2014 A1
20140142401 Al-Ali et al. May 2014 A1
20140142402 Al-Ali et al. May 2014 A1
20140163344 Al-Ali Jun 2014 A1
20140163402 Lamego et al. Jun 2014 A1
20140166076 Kiani et al. Jun 2014 A1
20140171763 Diab Jun 2014 A1
20140180038 Kiani Jun 2014 A1
20140180154 Sierra et al. Jun 2014 A1
20140194709 Al-Ali et al. Jul 2014 A1
20140194711 Al-Ali Jul 2014 A1
20140194766 Al-Ali et al. Jul 2014 A1
20140200420 Al-Ali Jul 2014 A1
20140200422 Weber et al. Jul 2014 A1
20140206963 Al-Ali Jul 2014 A1
20140213864 Abdul-Hafiz et al. Jul 2014 A1
20140243627 Diab et al. Aug 2014 A1
20140266790 Al-Ali et al. Sep 2014 A1
20140275808 Poeze et al. Sep 2014 A1
20140275835 Lamego et al. Sep 2014 A1
20140275871 Lamego et al. Sep 2014 A1
20140275872 Merritt et al. Sep 2014 A1
20140275881 Lamego et al. Sep 2014 A1
20140288400 Diab et al. Sep 2014 A1
20140296664 Bruinsma et al. Oct 2014 A1
20140303520 Telfort et al. Oct 2014 A1
20140309506 Lamego et al. Oct 2014 A1
20140309559 Telfort et al. Oct 2014 A1
20140316228 Blank et al. Oct 2014 A1
20140323825 Al-Ali et al. Oct 2014 A1
20140330092 Al-Ali et al. Nov 2014 A1
20140330098 Merritt et al. Nov 2014 A1
20140330099 Al-Ali et al. Nov 2014 A1
20140333440 Kiani Nov 2014 A1
20140336481 Shakespeare et al. Nov 2014 A1
20140343436 Kiani Nov 2014 A1
Foreign Referenced Citations (78)
Number Date Country
3244695 Oct 1985 DE
0419 223 Mar 1991 EP
0569 670 Feb 1993 EP
0675541 Oct 1995 EP
0469395 Feb 1996 EP
0417447 Oct 1997 EP
0606356 Jun 1998 EP
0734221 Jul 1998 EP
1895892 May 2010 EP
2305104 Apr 2011 EP
6128172 Feb 1986 JP
62000324 Jan 1987 JP
63275327 Nov 1988 JP
64500495 Feb 1989 JP
2145457 Dec 1990 JP
05207993 Aug 1993 JP
H06-178776 Jun 1994 JP
6505903 Jul 1994 JP
6237013 Aug 1994 JP
H07-391 Jan 1995 JP
H07-171089 Jul 1995 JP
H07-171090 Jul 1995 JP
7281618 Oct 1995 JP
07325546 Dec 1995 JP
9192120 Jul 1997 JP
10500026 Jun 1998 JP
10216112 Aug 1998 JP
10509352 Sep 1998 JP
10269344 Oct 1998 JP
10295676 Nov 1998 JP
10305026 Nov 1998 JP
11163412 Jun 1999 JP
11164826 Jun 1999 JP
11506834 Jun 1999 JP
11183377 Jul 1999 JP
2000116625 Apr 2000 JP
2001-504256 Mar 2001 JP
2002516689 Jun 2002 JP
2002228579 Aug 2002 JP
2002525151 Aug 2002 JP
2002315739 Oct 2002 JP
2003507718 Feb 2003 JP
2003084108 Mar 2003 JP
2003521985 Jul 2003 JP
2004070179 Mar 2004 JP
2004226277 Aug 2004 JP
2004510467 Aug 2004 JP
2004296736 Oct 2004 JP
2004532526 Oct 2004 JP
2004327760 Nov 2004 JP
2005501589 Jan 2005 JP
2005253478 Sep 2005 JP
4879913 Dec 2011 JP
WO 8801150 Feb 1988 WO
WO 8802020 Feb 1988 WO
WO 9216142 Oct 1992 WO
WO 9306776 Apr 1993 WO
WO 9516387 Jun 1995 WO
WO 9613208 May 1996 WO
WO 9701985 Jan 1997 WO
WO 9729678 Aug 1997 WO
WO 9729710 Aug 1997 WO
WO 9843071 Oct 1998 WO
WO 0018290 Apr 2000 WO
WO 0042911 Jul 2000 WO
WO 0059374 Oct 2000 WO
WO 0113790 Mar 2001 WO
WO 0130414 May 2001 WO
WO 0158347 Aug 2001 WO
WO 0217780 Mar 2002 WO
WO 0217780 Mar 2002 WO
WO 0226123 Apr 2002 WO
WO 02089664 Nov 2002 WO
WO 03020129 Mar 2003 WO
WO 03068060 Aug 2003 WO
WO 2004034898 Apr 2004 WO
WO 2005011488 Feb 2005 WO
WO 2006094168 Sep 2006 WO
Non-Patent Literature Citations (44)
Entry
Burritt, Mary F.; Current Analytical Approaches to Measuring Blood Analytes; vol. 36; No. 8(B); 1990.
European Examination Report dated Apr. 1, 2010, re EP App. No. 08 744 412.1 / 2319.
European Examination Report dated Mar. 18, 2011, re EP App. No. 08 744 412.1 / 2319.
European Examination Report dated Sep. 2, 2010, re EP App. No. 08 744 412.1 / 2319.
European Extended Search Report re EPO App. No. 10162402.1, SR dated Aug. 9, 2010.
Hall, et al., Jeffrey W.; Near/Infrared Spectrophotometry: A New Dimension in Clinical Chemistry; vol. 38; No. 9; 1992.
International Search Report for PCT/US2006/007516, mailed on Jan. 11, 2007, in 4 pages.
Japanese First Office Action (Notice of Reasons for Rejection), re JP App. No. 2007/558207, dated Jun. 28, 2011.
Japanese First Office Action (Notice of Reasons for Rejection), re JP App. No. 2007/558247, dated Jun. 28, 2011.
Japanese Office Action (Notice of Allowance), re JP App. No. 2007/558247, dated Oct. 24, 2011.
Japanese Office Action (Notice of Reasons for Rejection) re JP App. No. 2007/558246, dated Jun. 28, 2011.
Japanese Office Action (Notice of Reasons for Rejection), re JP App. No. 2007/558238, dated Jun. 28, 2011.
Japanese Office Action re JP Application No. 2007/558249, dated Jul. 13, 2011.
Japanese Office Action re JP Application No. 2007/558249, dated Nov. 8, 2011.
Japanese Office Action re JP Application No. JP 2007/558208, dated Aug. 23, 2011.
Japanese Office Action re JP Application No. JP 2007/558248, dated Nov. 8, 2011.
Japanese Office Action re JP Application No. 2007/558209, dated Oct. 25, 2011.
Japanese Office Action re JP Application No. 2007/558245, dated Oct. 25, 2011.
Japanese Office Action, re JP Application No. 2007/558237, dated Aug. 1, 2011.
Kuenstner, et al., J. Todd; Measurement of Hemoglobin in Unlysed Blood by Near/Infrared Spectroscopy; vol. 48; No. 4, 1994.
Manzke, et al., B., Multi Wavelength Pulse OXimetry in the Measurement of Hemoglobin Fractions; vol. 2676, date unknown.
Naumenko, E. K.; Choice of Wavelengths for Stable Determination of Concentrations of Hemoglobin Derivatives from Absorption Spectra of Erythrocytes; vol. 63; No. 1; pp. 60/66 Jan. / Feb. 1996; Original article submitted Nov. 3, 1994.
Patent Cooperation Treaty (PCT) International Search Report; PCT/US 2006/007389; Date of Mailing Jul. 17, 2006; pp. 1/9.
PCT International Search Report; PCT/US2006/007387; Date of Mailing Jul. 17, 2006; pp. 1/9.
PCT International Search Report; PCT/US2006/007388; Date of Mailing Jul. 17, 2006; pp. 1/9.
PCT International Search Report; PCT/US2006/007506; Date of Mailing Jul. 17, 2006; pp. 1/10.
PCT International Search Report; PCT/US2006/007536; Date of Mailing Jul. 17, 2006; pp. 1/9.
PCT International Search Report; PCT/US2006/007537; Date of Mailing Jul. 17, 2006; pp. 1/10.
PCT International Search Report; PCT/US2006/007538; Date of Mailing Jul. 17, 2006; pp. 1/9.
PCT International Search Report; PCT/US2006/007539; Date of Mailing Jul. 17, 2006; pp. 1/9.
PCT International Search Report; PCT/US2006/007540; Date of Mailing Jul. 17, 2006; pp. 1/9.
PCT International Search Report; PCT/US2006/007958; Date of Mailing Jul. 17, 2006; pp. 1/8.
PCT Search Report of International Application No. PCT/US2008/058327, Mailing Date of Jun. 30, 2009, in 12 pages.
PCT Search Report of International Application No. PCT/US2008/058327, Mailing Date of Aug. 12, 2008, in 6 pages.
Schmitt, Joseph M.; Simple Photon Diffusion Anaylsis of the Effects of Multiple Scattering on Pulse Oximetry; Mar. 14, 1991; revised Aug. 30, 1991.
Schmitt, Joseph M.; Zhou, Guan/Xiong; Miller, Justin, Measurement of Blood Hematocrit by Dual/wavelength Near/IR Photoplethysmography, published May 1992, Proc. SPIE vol. 1641, p. 150/161, Physiological Monitoring and Early Detection Diagnostic Methods, Thomas S. Mang; Ed. (SPIE homepage), in 12 pages.
Schnapp, et al., L.M.; Pulse Oximetry. Uses and Abuses; Chest 1990; 98; 1244/1250001 10.1378/Chest.98.5.1244.
US 8,845,543, 09/2014, Diab et al. (withdrawn).
“Application Note 84 Use of Add-Only Memory for Secure Storage of Monetary Equivalent Data,” Dallas Semiconductor, in 5 pages.
Dallas Semiconductor Corp: DS2430A Announcement, retrieved Jun. 10, 1998, in 2 pages. <https://web.archive.org/web/19980610045525/http://dalsemi.com/News—Center/New—Products/1996/2430a.html>.
Favennec, J.M. “Smart sensors in industry.” J. Phys. E: Sci. Instrum. 20 (1987): pp. 1087-1090.
Jones, K.L., et al. “A Protocol for Automatic Sensor Detection and Identification in a Wireless Biodevice Network.” 1998, 6 pages.
“Medical.” 50 Ways to Touch Memory. 3rd ed. Dallas: Dallas Semiconductor Corporation, 1994: pp. 24-25. Print.
Subramanian, S., et al. “Design for Constraint Violation Detection in Safety-Critical Systems.” 1998: pp. 1-8.
Related Publications (1)
Number Date Country
20140142402 A1 May 2014 US
Provisional Applications (4)
Number Date Country
60657596 Mar 2005 US
60657281 Mar 2005 US
60657268 Mar 2005 US
60657759 Mar 2005 US
Continuations (2)
Number Date Country
Parent 13477975 May 2012 US
Child 14052604 US
Parent 11367014 Mar 2006 US
Child 13477975 US